

# CITATION REPORT

List of articles citing

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report

DOI: 10.1038/nm840

Nature Medicine, 2003, 9, 448-52.

**Source:** <https://exaly.com/paper-pdf/35290846/citation-report.pdf>

**Version:** 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1355	Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. <b>2003</b> , 25, 611-6		94
1354	[Vaccination against Alzheimer disease?]. <b>2003</b> , 115, 279-80		2
1353	Vaccine trial in Alzheimer's disease is halted. <b>2003</b> , 3, 371-2		2
1352	Treatment of Alzheimer's disease: current status and new perspectives. <b>2003</b> , 2, 539-47		590
1351	Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. <b>2003</b> , 33, 3232-41		56
1350	Prion diseases: from molecular biology to intervention strategies. <b>2003</b> , 4, 1268-84		33
1349	Alzheimer vaccine: an update. <b>2003</b> , 25, 1025-1025		
1348	Therapeutic approaches to protein-misfolding diseases. <b>2003</b> , 426, 905-9		726
1347	Attack on amyloid. <b>2003</b> , 4, 747-51		3
1346	Battle of the mind. <b>2003</b> , 422, 370-2		2
1345	Alzheimer disease's double-edged vaccine. <i>Nature Medicine</i> , <b>2003</b> , 9, 389-90	50.5	46
1344	Alzheimer's disease: Mechanisms and development of therapeutic strategies. <b>2003</b> , 3, 175-188		
1343	Clinically tested drugs for Alzheimer's disease. <b>2003</b> , 12, 1143-51		20
1342	Remodelling of cerebrospinal fluid lipoproteins after subarachnoid hemorrhage. <b>2003</b> , 170, 141-6		12
1341	Yin and Yang: complement activation and regulation in Alzheimer's disease. <b>2003</b> , 70, 463-72		78
1340	Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. <b>2003</b> , 38, 547-54		677
1339	Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. <b>2003</b> , 40, 1087-93		604

1338	A new role for astrocytes: beta-amyloid homeostasis and degradation. <b>2003</b> , 9, 281-2	46
1337	Increased T cell reactivity to amyloid $\beta$ protein in older humans and patients with Alzheimer disease. <b>2003</b> , 112, 415-422	221
1336	Vaccines for Alzheimer's disease: how close are we?. <b>2003</b> , 17, 457-74	35
1335	Pharmacotherapy is used to reduce opiate withdrawal symptoms and prevent relapse in patients addicted to heroin. <b>2003</b> , 19, 13-17	
1334	Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. <b>2003</b> , 61, 46-54	1131
1333	Setback for an Alzheimer's disease vaccine: lessons learned. <b>2003</b> , 61, 7-8	19
1332	Metal chelation therapy for Alzheimer disease. <b>2003</b> , 60, 1678-9	15
1331	Immunotherapeutic approaches to Alzheimer's disease. <b>2003</b> , 302, 834-8	253
1330	Alzheimer's disease: from molecular pathogenesis to innovative therapies. <b>2003</b> , 3, 619-30	7
1329	Rapid induction of autoantibodies against Nogo-A and MOG in the absence of an encephalitogenic T cell response: implication for immunotherapeutic approaches in neurological diseases. <b>2003</b> , 17, 2275-7	28
1328	MSJAMA: Lessons and responses in Alzheimer disease research. <b>2003</b> , 290, 115	1
1327	Mouse models of Alzheimer's disease: the long and filamentous road. <b>2003</b> , 25, 590-600	46
1326	Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. <b>2003</b> , 126, 1935-9	105
1325	MSJAMA: Industry funding of clinical trials: benefit or bias?. <b>2003</b> , 290, 113-4	62
1324	Dementia update 2003. <b>2003</b> , 17, 245-58	27
1323	Cortical and Leptomeningeal Cerebrovascular Amyloid and White Matter Pathology in Alzheimer's Disease. <b>2003</b> , 9, 112-122	193
1322	Inflammatory disorders of the central nervous system. <b>2003</b> , 16, 347-50	3
1321	Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma <sup>-/-</sup> knock-out mice. <b>2003</b> , 23, 8532-8	191

1320	Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. <b>2003</b> , 23, 10879-83			144
1319	Progress towards a vaccine for Huntington's disease. <b>2003</b> , 7, 569-70			13
1318	DNA in Disease, Diagnostics, and Medicine. <b>2004</b> , 235-269			
1317	An unconventional hypothesis of oxidation in Alzheimer's disease: intersections with excitotoxicity. <b>2004</b> , 9, 3286-95			20
1316	. <b>2004</b> ,			2
1315	Cerebral hypoperfusion and amyloid-induced synergistic impairment of hippocampal CA1 synaptic efficacy and spatial memory in young adult rats. <i>Journal of Alzheimer's Disease</i> , <b>2004</b> , 6, 355-66; discussion 443-9	4.3		11
1314	The Amyloid Hypothesis and the clearance and degradation of Alzheimer's beta-peptide. <i>Journal of Alzheimer's Disease</i> , <b>2004</b> , 6, 303-14	4.3		19
1313	[Immunotherapy of Alzheimer's disease. Results of experimental investigations and treatment of perspectives]. <i>Fortschritte Der Neurologie Psychiatrie</i> , <b>2004</b> , 72, 204-19	0.5		2
1312	Future directions in the treatment of Alzheimer's disease. <b>2004</b> , 13, 303-14			21
1311	Hormone therapy and Alzheimer's disease: benefit or harm?. <b>2004</b> , 5, 389-406			32
1310	Therapeutic potential of oxidant mechanisms in Alzheimer's disease. <b>2004</b> , 4, 995-1004			13
1309	Secretases as therapeutic targets in Alzheimer's disease: patents 2000 -2004. <b>2004</b> , 14, 1403-1420			12
1308	Immunotherapy for Alzheimer's disease. <b>2004</b> , 101 Suppl 2, 14657-62			142
1307	Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. <b>2004</b> , 75, 1472-4			261
1306	Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease. <b>2004</b> , 3, 717-25			14
1305	Depressive symptoms and cognitive decline--disentangling the effect of affect. <b>2004</b> , 75, 5			6
1304	Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. <i>Journal of Biological Chemistry</i> , <b>2004</b> , 279, 12876-82	5.4		572
1303	IgA antibodies of coeliac disease patients recognise a dominant T cell epitope of A-gliadin. <b>2004</b> , 53, 1274-8			14

1302 The direction of mental health care for the elderly. **2004**, 80, 187-9

1301 Identification of two immunogenic domains of the prion protein--PrP--which activate class II-restricted T cells and elicit antibody responses against the native molecule. **2004**, 76, 125-34 25

1300 An unusual cause of postoperative dyspnoea. **2004**, 53, 1278, 1286

1299 Neuronal structure is altered by amyloid plaques. **2004**, 15, 267-78 85

1298 Rheumatology and Immunology Therapy. **2004**, 5 5

1297 Assessment of the bioactivity of antibodies against beta-amyloid peptide in vitro and in vivo. **2004**, 1, 160-7 11

1296 Vaccines to remember: managing health in our twilight years. **2004**, 3, 497-500

1295 Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. **2004**, 172, 5168-74 55

1294 Protein chemistry. In the footsteps of alchemists. **2004**, 304, 1259-62 64

1293 Vaccines for conformational disorders. **2004**, 3, 279-90 11

1292 Molecular basis of Alzheimer's disease: From amyloid hypothesis to treatment in the foreseeable future. **2004**, 4, S27-S31 3

1291 Protein misfolding in neurodegenerative diseases. **2004**, 30, 215-24 80

1290 Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. **2004**, 19, 2703-10 110

1289 Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease. *Nature Medicine*, **2004**, 10, 117-8; author reply 118-9 50.5 43

1288 Reply to "Specificity of mechanisms for plaque removal after A beta immunotherapy for Alzheimer disease" *Nature Medicine*, **2004**, 10, 118-119 50.5 11

1287 International cooperation on xenotransplantation. *Nature Medicine*, **2004**, 10, 119 50.5 5

1286 Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. **2004**, 7, 954-60 321

1285 Therapeutic vaccination for chronic diseases: a new class of drugs in sight. **2004**, 3, 81-8 85

1284	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. <b>2004</b> , 9, 664-83		228
1283	Strategies for disease modification in Alzheimer's disease. <b>2004</b> , 5, 677-85		361
1282	Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. <b>2004</b> , 14, 11-20		447
1281	Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. <b>2004</b> , 3, 484-92		133
1280	Preconditioning and the developing brain. <b>2004</b> , 28, 389-95		49
1279	Overcoming antigen masking of anti-amyloidbeta antibodies reveals breaking of B cell tolerance by virus-like particles in amyloidbeta immunized amyloid precursor protein transgenic mice. <b>2004</b> , 5, 21		43
1278	Alzheimer's disease therapeutics: new approaches to an ageing problem. <b>2004</b> , 56, 203-8		4
1277	Current issues in the treatment of human diseases by mucosal tolerance. <b>2004</b> , 1029, 211-24		48
1276	Microglia as a potential bridge between the amyloid beta-peptide and tau. <b>2004</b> , 1035, 85-103		104
1275	Only cerebral capillary amyloid angiopathy correlates with Alzheimer pathology--a pilot study. <i>Acta Neuropathologica</i> , <b>2004</b> , 107, 83-90	14.3	135
1274	Glial reactions and the clearance of amyloid beta protein in the brains of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. <i>Acta Neuropathologica</i> , <b>2004</b> , 107, 389-98	14.3	26
1273	Neuroinflammatory perspectives on the two faces of Alzheimer's disease. <b>2004</b> , 111, 281-94		151
1272	Gene-environment interplay in neurogenesis and neurodegeneration. <b>2004</b> , 6, 415-34		10
1271	Stress kinases involved in tau phosphorylation in Alzheimer's disease, tauopathies and APP transgenic mice. <b>2004</b> , 6, 469-75		43
1270	Current progress in beta-amyloid immunotherapy. <b>2004</b> , 16, 599-606		119
1269	The immune component of brain disease. <b>2004</b> , 16, 584-586		
1268	Toward modeling hemorrhagic and encephalitic complications of Alzheimer amyloid-beta vaccination in nonhuman primates. <b>2004</b> , 16, 607-15		25
1267	Is amyloid plaque imaging the key to monitoring brain pathology of Alzheimer's disease in vivo?. <b>2004</b> , 31, 1540-3		4

1266	The immunotherapy of Alzheimer's disease. <b>2004</b> , 1, 2	18
1265	Is immunotherapy an effective treatment for Alzheimer's disease?. <b>2004</b> , 1, 3	3
1264	Immunotherapy as a therapeutic treatment for neurodegenerative disorders. <b>2003</b> , 87, 801-8	30
1263	Clinical manifestations of cerebral amyloid angiopathy-related inflammation. <b>2004</b> , 55, 250-6	290
1262	Anti-Abeta: The good, the bad, and the unforeseen. <b>2004</b> , 75, 301-6	31
1261	Microglia and Alzheimer's disease pathogenesis. <b>2004</b> , 77, 1-8	255
1260	Effect of age on the duration and extent of amyloid plaque reduction and microglial activation after injection of anti-Abeta antibody into the third ventricle of TgCRND8 mice. <b>2004</b> , 78, 732-41	22
1259	High mobility group box protein-1 inhibits microglial Abeta clearance and enhances Abeta neurotoxicity. <b>2004</b> , 78, 880-91	64
1258	Alzheimer's disease and immune activation: A translational perspective. <b>2004</b> , 35, 193-201	
1257	Metal-protein attenuating compounds and Alzheimer's disease. <b>2004</b> , 13, 1585-92	53
1256	Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. <b>2004</b> , 43, 9999-10007	7
1255	Toward Alzheimer therapies based on genetic knowledge. <b>2004</b> , 55, 15-25	32
1254	Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease*1Pro-CAA position statement. <b>2004</b> , 25, 589-589	2
1253	Recent progress in Alzheimer's disease: animal models lead the way. <b>2004</b> , 1, 145-149	1
1252	Single chain variable fragments against beta-amyloid (Abeta) can inhibit Abeta aggregation and prevent abeta-induced neurotoxicity. <b>2004</b> , 43, 6959-67	105
1251	Alzheimer's disease: facing the biological complexity to treat the disease. <b>2004</b> , 50, 381-3	
1250	Biomarkers of Alzheimer disease in plasma. <b>2004</b> , 1, 226-34	212
1249	Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. <i>Journal of Neuroinflammation</i> , <b>2004</b> , 1, 24	10.1 301

1248	On the horizon: pathways for drug development in Alzheimer's disease. <b>2004</b> , 20, 141-52	2
1247	Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. <b>2004</b> , 188, 52-64	85
1246	The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. <b>2004</b> , 18, 407-13	408
1245	Species-specific immune response to immunization with human versus rodent A beta peptide. <b>2004</b> , 25, 1141-51	24
1244	Tangles precede plaques but don't cause them. <b>2004</b> , 25, 741-2; discussion 743-6	8
1243	Lessons from the AN 1792 Alzheimer vaccine: lest we forget. <b>2004</b> , 25, 609-15	75
1242	The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. <b>2004</b> , 25, 675-83	168
1241	Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. <b>2004</b> , 25, 589-97; discussion 603-4	136
1240	Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease. <b>2004</b> , 25, 605-8	30
1239	Is the A beta vaccine the answer?. <b>2004</b> , 25, 617-8	2
1238	A beta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. <b>2004</b> , 43, 321-32	670
1237	Clearing tau pathology with A beta immunotherapy--reversible and irreversible stages revealed. <b>2004</b> , 43, 293-4	17
1236	Deciphering the molecular basis of memory failure in Alzheimer's disease. <b>2004</b> , 44, 181-93	1004
1235	Differences in the immune response to long term A beta vaccination in C57BL/6 and B6D2F1 mice. <b>2004</b> , 22, 4075-83	18
1234	Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. <b>2004</b> , 165, 283-97	198
1233	Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive A beta immunotherapy on their clearance. <b>2004</b> , 165, 987-95	119
1232	Microglial activation facilitates A beta plaque removal following intracranial anti-A beta antibody administration. <b>2004</b> , 15, 11-20	166
1231	Reduced levels of A beta 40 and A beta 42 in brains of smoking controls and Alzheimer's patients. <b>2004</b> , 15, 351-60	61



1230 Amyloid and tau protein. **2004**, 4, S62-S69

1229 BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. **2004**, 41, 27-33 457

1228 Anti-amyloid activity of neprilysin in plaque-bearing mouse models of Alzheimer's disease. **2004**, 562, 16-21 32

1227 Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. **2004**, 10, 1469-92 218

1226 The systemic amyloidoses. **2004**, 16, 67-75 100

1225 Current concepts and future prospects for Alzheimer disease vaccines. **2004**, 18, 38-43 21

1224 Development of a safe oral Abeta vaccine using recombinant adeno-associated virus vector for Alzheimer's disease. *Journal of Alzheimer's Disease*, **2004**, 6, 483-8 43 75

1223 SMI 4th Annual Conference on Neurodegenerative Disorders: a focus on Alzheimer's and Parkinson's disease. **2004**, 13, 1369-73 2

1222 Is amyloid- $\beta$  peptide immunization clinically effective in patients with Alzheimer's disease?. **2005**, 1, 84-85 9

1221 Proving inventorship: the importance of the inventor/laboratory notebook. **2005**, 25, S99

1220 Strategies for success in drug development. **2005**, 25, S100-S102

1219 Crucial factors in commercial success for ophthalmic drugs. **2005**, 25, S109

1218 Utilizing advanced imaging and surrogate markers across the spectrum of Alzheimer's disease. **2005**, 10, 13-6 13

1217 Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease. *Journal of Alzheimer's Disease*, **2004**, 6, 623-32; discussion 673-81 43 45

1216 Immunotherapy for Alzheimer's disease and other dementias. **2005**, 18, 720-5 13

1215 Dementia update 2005. **2005**, 19, 100-17 44

1214 Alzheimer's Disease: Current and Future Treatments. **2005**, 329-354 1

1213 An Overview of Protein Misfolding Diseases. 1093-1113 3

1212	Challenges associated with clinical trials for inherited and orphan retinal diseases. <b>2005</b> , 25, S10-S12	1
1211	Drug delivery systems for treating orphan retinal diseases. <b>2005</b> , 25, S44-S45	
1210	New paradigms for drug discovery. <b>2005</b> , 25, S55	
1209	Design of phase III clinical trials for treatments of orphan retinal diseases: an overview of considerations. <b>2005</b> , 25, S69-S71	2
1208	Surmountable challenges in translating pigment epithelium-derived factor (PEDF) therapy from animal models to clinical trials for retinal degenerations. <b>2005</b> , 25, S29-S30	2
1207	T-cell-based vaccination against neurodegeneration: a new therapeutic approach. <b>2005</b> , 25, S33-S35	8
1206	Challenges in the pursuit of therapeutic product development. <b>2005</b> , 25, S46	
1205	Adenovector pigment epithelium-derived factor (AdPEDF) delivery for wet age-related macular degeneration. <b>2005</b> , 25, S48-S49	4
1204	The consortium project to treat RPE65 deficiency in humans. <b>2005</b> , 25, S60	6
1203	Cooperation between private and public sectors leads to an intraocular retinal implant. <b>2005</b> , 25, S63	
1202	A network of patients with orphan retinal diseases for clinical trials: goals, structure, challenges. <b>2005</b> , 25, S66-S67	
1201	Fostering research partnerships: a perspective from The Office of Rare Diseases (ORD). <b>2005</b> , 25, S86	1
1200	Federal regulatory issues: investigational new drugs in ophthalmology. <b>2005</b> , 25, S88	
1199	The Food and Drug Administration's Office of Orphan Products Development: incentives, grants, and special designations speed therapies for orphan diseases. <b>2005</b> , 25, S89-S90	4
1198	Intellectual property in drug development: a report from a breakout session. <b>2005</b> , 25, S95	
1197	Mechanics of the Food and Drug Administration's Form 1571: investigational new drug application. <b>2005</b> , 25, S96-S97	2
1196	Key considerations for seeking product development funding. <b>2005</b> , 25, S110	
1195	Role of venture capitalists in funding clinical trials. <b>2005</b> , 25, S112-S113	1

1194	Beyond basic research for inherited and orphan retinal diseases: successes and challenges. <b>2005</b> , 25, S15-S17	5
1193	Survival factors for treatment of retinal degenerative disorders: preclinical gains and issues for translation into clinical studies. <b>2005</b> , 25, S25-S26	14
1192	Usher syndrome type 1: genotype-phenotype relationships. <b>2005</b> , 25, S40-S42	5
1191	Retinal researchers have reasons to be optimistic. <b>2005</b> , 25, S43	1
1190	Strategies for delivery of rod-derived cone viability factor. <b>2005</b> , 25, S47	4
1189	Importance of genotyping in clinical trials of inherited and orphan retinal diseases. <b>2005</b> , 25, S74	
1188	Governmental, university, pharmaceutical, and foundation partnerships to advance translational research in retinal disease. <b>2005</b> , 25, S82	1
1187	Intellectual property: patents and transfer agreements preceding clinical trials and commercialization. <b>2005</b> , 25, S91-S94	
1186	Announcements. <b>2005</b> , 19, 117	
1185	Photoreceptor cell rescue in inherited and orphan retinal diseases: disease-specific requirements. <b>2005</b> , 25, S13-S14	
1184	Challenges in genetic testing for clinical trials of inherited and orphan retinal diseases. <b>2005</b> , 25, S72-S73	5
1183	Fostering partnerships: a perspective from the National Institute of Neurologic Disorders and Stroke (NINDS). <b>2005</b> , 25, S83	
1182	Licensing Compounds: lessons from ISTA Pharmaceuticals. <b>2005</b> , 25, S98	
1181	Inherited and orphan retinal diseases: phenotypes, genotypes, and probable treatment groups. <b>2005</b> , 25, S4-S7	12
1180	Effect of gene expression on cone survival in retinitis pigmentosa. <b>2005</b> , 25, S21-S24	3
1179	Saving cone cells in hereditary rod diseases: a possible role for rod-derived cone viability factor (RdCVF) therapy. <b>2005</b> , 25, S38-S39	22
1178	Clinical trials with micronutrients and mineral supplements for retinal degenerations: a summary of a breakout session. <b>2005</b> , 25, S50-S51	1
1177	A randomized placebo-controlled clinical trial of docosahexaenoic acid (DHA) supplementation for X-linked retinitis pigmentosa. <b>2005</b> , 25, S52-S54	9

1176	Screening existing drugs for neurodegeneration: The National Institute of Neurologic Disorders and Stroke (NINDS) model. <b>2005</b> , 25, S56-S57	9
1175	High-throughput compound screening and discovery in an academic setting. <b>2005</b> , 25, S58-S59	
1174	Preclinical assessment programs to evaluate potential therapies for the treatment of orphan retinal diseases. <b>2005</b> , 25, S64-S65	
1173	National and international patient networks: standardization of phenotype and genotype definitions. <b>2005</b> , 25, S68	
1172	Business modeling. <b>2005</b> , 25, S111	1
1171	Cellular mechanisms of retinal degenerations: RPE65, ABCA4, RDS, and bicarbonate transporter genes as examples. <b>2005</b> , 25, S18-S20	2
1170	Animal models as tools for screening candidate drugs. <b>2005</b> , 25, S36-S37	1
1169	Clinical trials of neuroprotective agents in glaucoma. <b>2005</b> , 25, S78-S79	2
1168	Alzheimer disease: therapeutic targets for clinical trials. <b>2005</b> , 25, S80-S81	1
1167	Fostering partnerships: The National Institutes of Health (NIH) Mission. <b>2005</b> , 25, S84-S85	
1166	Fostering partnerships: an industry perspective. <b>2005</b> , 25, S87	
1165	The national eye institute: translational clinical research initiatives on inherited and orphan retinal diseases: personal observations. <b>2005</b> , 25, S8-S9	2
1164	Ciliary neurotrophic factor therapy for inherited retinal diseases: pros and cons. <b>2005</b> , 25, S27-S28	8
1163	Inhibition of poly(adenosine diphosphate-ribose) polymerase (PARP) in experimental models of neurologic diseases: cell death prevention. <b>2005</b> , 25, S31-S32	8
1162	The role of RPE65 in inherited retinal diseases. <b>2005</b> , 25, S61-S62	6
1161	Failures and successes of clinical trials for Parkinson disease treatments. <b>2005</b> , 25, S75-S77	2
1160	Attracting pharmaceutical companies as partners in drug development. <b>2005</b> , 25, S103	
1159	An overview: attracting partners in the pharmaceutical industry. <b>2005</b> , 25, S104	

1158	Hurdles and opportunities for a venture capitalist investing in therapies for orphan retinal diseases. <b>2005</b> , 25, S105-S108		
1157	The Amyloid $\beta$ Protein. 384-491		2
1156	Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. <b>2005</b> , 33, 553-8		50
1155	Mechanisms of memory loss in Abeta and tau mouse models. <b>2005</b> , 33, 591-4		38
1154	T-cells in Alzheimer's disease. <b>2005</b> , 7, 255-64		136
1153	Correlation between tau phosphorylation sites and tangle morphology in Alzheimer's disease. <b>2005</b> , 5, 22-35		2
1152	Illustration of dynamic changes in Alzheimer pathology: from mild cognitive impairment to terminal stage. <i>Neuropathology</i> , <b>2005</b> , 25, 285-7	2	4
1151	Attenuation of Abeta deposition in the entorhinal cortex of normal elderly individuals associated with tobacco smoking. <b>2005</b> , 31, 522-35		27
1150	Rational targeting for prion therapeutics. <b>2005</b> , 6, 23-34		72
1149	Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. <i>Nature Medicine</i> , <b>2005</b> , 11, 556-61	50.5	443
1148	The immune system, amyloid-beta peptide, and Alzheimer's disease. <b>2005</b> , 205, 244-56		51
1147	Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. <b>2005</b> , 86, 173-85		41
1146	Emerging prospects for the disease-modifying treatment of Alzheimer's disease. <b>2005</b> , 69, 1001-8		45
1145	Metabolism of amyloid-beta peptide and Alzheimer's disease. <b>2005</b> , 108, 129-48		161
1144	Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. <b>2005</b> , 58, 430-5		113
1143	Cerebral amyloid angiopathy: both viper and maggot in the brain. <b>2005</b> , 58, 348-50		21
1142	Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer's disease and other neurodegenerative diseases. <b>2005</b> , 81, 412-25		73
1141	Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. <i>Acta Neuropathologica</i> , <b>2005</b> , 109, 449-55	14.3	130

1140	Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms. <i>Acta Neuropathologica</i> , <b>2005</b> , 110, 345-59	14.3	169
1139	Emerging treatment strategies for alzheimer's disease. <b>2005</b> , 3, 15-19		
1138	Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. <b>2005</b> , 8, 25-50		63
1137	A computational positron emission tomography simulation model for imaging beta-amyloid in mice. <b>2005</b> , 7, 69-77		8
1136	Mecanismos neurobiológicos de la enfermedad de Alzheimer. <b>2005</b> , 43, 123		1
1135	Neurodegeneration. <b>2005</b> , 335-355		
1134	Selected genetically engineered models relevant to human neurodegenerative disease. <b>2005</b> , 176-195		1
1133	A genetic outline of the pathways to cell death in Alzheimer's disease, Parkinson's disease, frontal dementias and related disorders. <b>2005</b> , 222-226		
1132	Alzheimer's disease: overview. <b>2005</b> , 416-432		
1131	The neuropathology of Alzheimer's disease in the year 2005. <b>2005</b> , 433-440		11
1130	The role of $\beta$ -amyloid in Alzheimer's disease. <b>2005</b> , 452-458		
1129	eCAM benefits from diversity that derives from CAM. <b>2005</b> , 2, 263-5		3
1128	Tratamento farmacológico da doença de Alzheimer. <b>2005</b> , 32, 137-148		11
1127	Immunotherapy for Alzheimers Disease: Potential Problems and Possible Solutions. <b>2005</b> , 1, 139-155		11
1126	Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. <b>2005</b> , 2, e355		157
1125	Towards practical cognitive assessment for detection of early dementia: a 30-minute computerized battery discriminates as well as longer testing. <b>2005</b> , 2, 117-24		39
1124	Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. <b>2005</b> , 64, 94-101		293
1123	Mechanisms of cell signaling and inflammation in Alzheimer's disease. <b>2005</b> , 4, 247-56		136

1122	Immunization therapy for Alzheimer disease?. <b>2005</b> , 64, 10-2	8
1121	IgG-assisted age-dependent clearance of Alzheimer's amyloid beta peptide by the blood-brain barrier neonatal Fc receptor. <b>2005</b> , 25, 11495-503	198
1120	LPS receptor (CD14): a receptor for phagocytosis of Alzheimer's amyloid peptide. <b>2005</b> , 128, 1778-89	271
1119	Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. <b>2005</b> , 25, 11125-32	148
1118	Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. <b>2005</b> , 64, 1553-62	1064
1117	Beyond the signal sequence: protein routing in health and disease. <b>2005</b> , 26, 479-503	68
1116	Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. <b>2005</b> , 64, 1563-72	469
1115	Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. <b>2005</b> , 64, 129-31	336
1114	A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. <b>2005</b> , 2, 255-60	58
1113	Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?. <b>2005</b> , 10, 817-25	33
1112	Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. <b>2005</b> , 25, 629-36	278
1111	Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. <b>2005</b> , 174, 1580-6	170
1110	Molecular neurology of prion disease. <b>2005</b> , 76, 906-19	156
1109	Neuronal and nonneuronal quantitative BACE immunocytochemical expression in the entorhinohippocampal and frontal regions in Alzheimer's disease. <b>2005</b> , 19, 171-83	40
1108	Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. <b>2005</b> , 175, 6211-8	52
1107	Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. <b>2005</b> , 2, 36-43	30
1106	Clinical observations with AN-1792 using TAPIR analyses. <b>2005</b> , 2, 273-6	16
1105	Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease. <b>2005</b> , 27, 869-81	100

1104	Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. <b>2005</b> , 128, 500-15	230
1103	The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. <b>2005</b> , 115, 1121-9	178
1102	Refining an Alzheimer's vaccine to avoid an inflammatory response. <b>2005</b> , 5, 809-16	5
1101	The development of anti-amyloid therapy for Alzheimer's disease : from secretase modulators to polymerisation inhibitors. <b>2005</b> , 19, 989-96	68
1100	beta-site specific intrabodies to decrease and prevent generation of Alzheimer's Abeta peptide. <b>2005</b> , 168, 863-8	92
1099	Altered APP processing in PDAPP (Val717 --> Phe) transgenic mice yields extended-length Abeta peptides. <b>2005</b> , 44, 13807-19	25
1098	Deglycosylation of anti-beta amyloid antibodies inhibits microglia activation in BV-2 cellular model. <b>2005</b> , 20, 303-13	9
1097	Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. <b>2005</b> , 11, 464-72	107
1096	Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice. <b>2005</b> , 20, 814-22	124
1095	Efficacy of anti-Abeta antibody isotypes used for intracerebroventricular immunization in TgCRND8. <b>2005</b> , 375, 143-7	36
1094	Suppression of Abeta deposition in brain by peripheral administration of Fab fragments of anti-seed antibody. <b>2005</b> , 335, 45-7	28
1093	Induction of anti-inflammatory immune response by an adenovirus vector encoding 11 tandem repeats of Abeta1-6: toward safer and effective vaccines against Alzheimer's disease. <b>2005</b> , 336, 84-92	31
1092	Microglia and neuroprotection: implications for Alzheimer's disease. <b>2005</b> , 48, 234-9	192
1091	Modulation of Alzheimer's pathology by cerebro-ventricular grafting of hybridoma cells expressing antibodies against Abeta in vivo. <b>2005</b> , 579, 753-6	7
1090	Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. <b>2005</b> , 579, 2564-8	42
1089	Neurovascular mechanisms of Alzheimer's neurodegeneration. <b>2005</b> , 28, 202-8	732
1088	HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. <b>2005</b> , 26, 393-407	40
1087	Human monoclonal antibodies against amyloid-beta from healthy adults. <b>2005</b> , 26, 597-606	46



1086	Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. <b>2005</b> , 130, 339-47		64
1085	Vascular consequences of passive Abeta immunization for Alzheimer's disease. Is avoidance of "malactivation" of microglia enough?. <i>Journal of Neuroinflammation</i> , <b>2005</b> , 2, 2	10.1	11
1084	The microglial "activation" continuum: from innate to adaptive responses. <i>Journal of Neuroinflammation</i> , <b>2005</b> , 2, 24	10.1	318
1083	Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , <b>2005</b> , 2, 28	10.1	29
1082	Transgenic models of Alzheimer's disease: learning from animals. <b>2005</b> , 2, 423-37		154
1081	Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease. <b>2005</b> , 2, 612-26		72
1080	Immunological aetiology of major psychiatric disorders: evidence and therapeutic implications. <b>2005</b> , 65, 1493-520		51
1079	Synthesis, solution conformation, and antibody recognition of oligotuftsin-based conjugates containing a beta-amyloid(4-10) plaque-specific epitope. <b>2005</b> , 16, 921-8		11
1078	Decreased serum amyloid beta(1-42) autoantibody levels in Alzheimer's disease, determined by a newly developed immuno-precipitation assay with radiolabeled amyloid beta(1-42) peptide. <b>2005</b> , 57, 813-6		58
1077	Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. <b>2005</b> , 229-230, 37-41		102
1076	Aberrant accentuation of neurofibrillary degeneration in the hippocampus of Alzheimer's disease with amyloid precursor protein 717 and presenilin-1 gene mutations. <b>2005</b> , 234, 55-65		10
1075	Developing novel immunogens for an effective, safe Alzheimer's disease vaccine. <b>2005</b> , 2, 267-72		24
1074	Interleukins, inflammation, and mechanisms of Alzheimer's disease. <b>2006</b> , 74, 505-30		62
1073	Alzheimer: 100 Years and Beyond. <b>2006</b> ,		5
1072	Prevention and Treatment of Age-related Diseases. <b>2006</b> ,		2
1071	Treatment and prevention of the amyloidoses: can the lessons learned be applied to sporadic inclusion-body myositis?. <b>2006</b> , 66, S110-3		6
1070	Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. <b>2006</b> , 169, 1048-63		176
1069	Tjalma's syndrome. <b>2006</b> , 367, 567-8		5

1068	Autopsy: not dead. <b>2006</b> , 367, 568		3
1067	Disease-modifying therapies in Alzheimer's disease: how far have we come?. <b>2006</b> , 66, 2075-93		61
1066	Intracranial administration of deglycosylated C-terminal-specific anti-Aβ antibody efficiently clears amyloid plaques without activating microglia in amyloid-depositing transgenic mice. <i>Journal of Neuroinflammation</i> , <b>2006</b> , 3, 11	10.1	36
1065	Boosting with intranasal dendrimeric Aβ <sub>1-15</sub> but not Aβ <sub>1-15</sub> peptide leads to an effective immune response following a single injection of Aβ <sub>1-40/42</sub> in APP-tg mice. <i>Journal of Neuroinflammation</i> , <b>2006</b> , 3, 14	10.1	18
1064	Interleukin-1 receptor 1 knockout has no effect on amyloid deposition in Tg2576 mice and does not alter efficacy following Aβ immunotherapy. <i>Journal of Neuroinflammation</i> , <b>2006</b> , 3, 17	10.1	8
1063	Current pharmacotherapy for Alzheimer's disease. <b>2006</b> , 57, 513-33		243
1062	Aβ-immunotherapy for Alzheimer's disease using mannan-amyloid-Beta peptide immunoconjugates. <b>2006</b> , 25, 571-80		24
1061	Imaging and in vivo quantitation of beta-amyloid: an exemplary biomarker for Alzheimer's disease?. <b>2006</b> , 59, 940-7		22
1060	Single chain Fv antibodies against the 25-35 Aβ fragment inhibit aggregation and toxicity of Aβ <sub>42</sub> . <b>2006</b> , 45, 11532-9		41
1059	Circulating biomarkers of cognitive decline and dementia. <b>2006</b> , 364, 91-112		106
1058	Amelioration of amyloid load by anti-Aβ single-chain antibody in Alzheimer mouse model. <b>2006</b> , 344, 79-86		37
1057	Modulation of microglial activation state following passive immunization in amyloid depositing transgenic mice. <b>2006</b> , 49, 190-4		41
1056	Novel approaches for immunotherapeutic intervention in Alzheimer's disease. <b>2006</b> , 49, 113-26		33
1055	Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. <b>2006</b> , 24, 157-65		117
1054	[Alzheimer's disease: cardiovascular risk factors must be assessed]. <b>2006</b> , 27, 21-31		8
1053	The peripheral benzodiazepine receptor (Translocator protein 18kDa) in microglia: from pathology to imaging. <b>2006</b> , 80, 308-22		307
1052	A hundred years of Alzheimer's disease research. <b>2006</b> , 52, 3-13		365
1051	Quantitative analysis of amyloid plaques in a mouse model of Alzheimer's disease by phase-contrast X-ray computed tomography. <b>2006</b> , 138, 1205-13		43

1050	Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. <b>2006</b> , 24, 2275-82		66
1049	Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. <b>2006</b> , 24, 2824-34		16
1048	Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. <b>2006</b> , 24, 6321-31		87
1047	Abeta species removal after abeta42 immunization. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2006</b> , 65, 1040-8	3.1	218
1046	Compensatory responses induced by oxidative stress in Alzheimer disease. <b>2006</b> , 39, 7-13		33
1045	From Primary Cultures to the Aging Organism: Lessons from Human T Lymphocytes. <b>2006</b> , 33-43		
1044	Vaccination to treat noninfectious diseases: surveying the opportunities. <b>2006</b> , 289-317		
1043	Immunotherapy for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2006</b> , 9, 425-32	4.3	47
1042	Neuronal death and rescue: neurotrophic factors and anti-apoptotic mechanisms. 271-292		3
1041	Alzheimer's disease, model systems and experimental therapeutics. 565-586		
1040	Alzheimer's Disease. <b>2006</b> ,		
1039	Mice as models: transgenic approaches and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2006</b> , 9, 133-49	4.3	79
1038	The primary care of Alzheimer disease. <b>2006</b> , 332, 314-33		7
1037	Neuropathology and Pathogenesis of Encephalitis Following Amyloid- $\beta$ Immunization in Alzheimer's Disease. <b>2006</b> , 2006, 186-188		1
1036	Dementia: What is it All About?. <b>2006</b> , 19, 433-40		1
1035	The human prion protein residue 129 polymorphism lies within a cluster of epitopes for T cell recognition. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2006</b> , 65, 1059-68	3.1	4
1034	Animal Models of Alzheimer's Disease. <b>2006</b> , 1-73		
1033	Immunotherapy for Alzheimer's disease and other dementias. <b>2006</b> , 29, 22-7		7

1032	Amyloid-beta immunotherapies in mice and men. <b>2006</b> , 20, 118-23		14
1031	Physical activity and cognition in old age. <b>2006</b> , 19, 190-3		71
1030	New developments in mild cognitive impairment and Alzheimer's disease. <b>2006</b> , 19, 552-8		17
1029	Reporters of Amyloid Structure. <b>2006</b> , 287-302		
1028	Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> , <b>2006</b> , 10, 1-7	4.3	138
1027	[Amyloid-beta protein vaccine therapy for alzheimer's disease]. <b>2006</b> , 95, 1122-8		
1026	Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. <b>2006</b> , 23, 2635-47		89
1025	Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages. <b>2006</b> , 24, 2530-42		81
1024	Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. <b>2005</b> , 15, 72-7		43
1023	Neurovascular pathways and Alzheimer amyloid beta-peptide. <b>2005</b> , 15, 78-83		85
1022	The Abeta hypothesis: leading us to rationally-designed therapeutic strategies for the treatment or prevention of Alzheimer disease. <b>2005</b> , 15, 84-7		82
1021	The cerebral beta-amyloid angiopathies: hereditary and sporadic. <b>2006</b> , 16, 30-9		153
1020	Mechanism of cerebral beta-amyloid angiopathy: murine and cellular models. <b>2006</b> , 16, 40-54		130
1019	The beta-amyloid peptide of Alzheimer's disease decreases adhesion of vascular smooth muscle cells to the basement membrane. <b>2006</b> , 96, 53-64		28
1018	Disease modifying therapy for AD?. <b>2006</b> , 99, 689-707		105
1017	Lysosome-associated membrane protein 1 (LAMP-1) in Alzheimer's disease. <b>2006</b> , 32, 505-16		54
1016	Regression stage senile plaques in the natural course of Alzheimer's disease. <b>2006</b> , 32, 539-56		28
1015	Can the immune system fight Alzheimer disease?. <i>Nature Medicine</i> , <b>2006</b> , 12, 755-6; discussion 756	50.5	3

1014	Amyloid at the blood vessel wall. <i>Nature Medicine</i> , <b>2006</b> , 12, 756-7	50.5	35
1013	Highly cited research papers on Alzheimer disease published in 2004. <i>Nature Medicine</i> , <b>2006</b> , 12, 757	50.5	
1012	Research Highlights. <i>Nature Medicine</i> , <b>2006</b> , 12, 768-769	50.5	
1011	Alzheimer disease: progress or profit?. <i>Nature Medicine</i> , <b>2006</b> , 12, 780-4	50.5	221
1010	Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. <i>Nature Medicine</i> , <b>2006</b> , 12, 801-8	50.5	306
1009	Immunology and immunotherapy of Alzheimer's disease. <b>2006</b> , 6, 404-16		262
1008	The genetics of the amyloidoses: interactions with immunity and inflammation. <b>2006</b> , 7, 439-49		8
1007	Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. <b>2006</b> , 13, 1068-79		86
1006	The expanding role of BDNF: a therapeutic target for Alzheimer's disease?. <b>2006</b> , 6, 8-15		126
1005	Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. <b>2006</b> , 1, 151-70		293
1004	The significance of neuroinflammation in understanding Alzheimer's disease. <b>2006</b> , 113, 1685-95		216
1003	Alzheimer 100--highlights in the history of Alzheimer research. <b>2006</b> , 113, 1603-23		91
1002	Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer's disease. <b>2006</b> , 63, 1538-52		74
1001	[Results from biomedical aging research. Trends and current examples from immunology]. <b>2006</b> , 49, 506-12		5
1000	New pathways in drug discovery for Alzheimer's disease. <b>2006</b> , 6, 372-8		12
999	Synaptic dysfunction and oxidative stress in Alzheimer's disease: emerging mechanisms. <b>2006</b> , 10, 796-805		68
998	Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. <b>2006</b> , 11, 931-8		154
997	Imaging Alzheimer's disease pathology: one target, many ligands. <b>2006</b> , 11, 1093-9		50

996	Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. <b>2006</b> , 5, 33-9	36
995	Understanding natural and pathological autoimmunity. <b>2006</b> , 174, 1-2	2
994	Active immunization trial in Abeta42-injected P301L tau transgenic mice. <b>2006</b> , 22, 50-6	18
993	Immunization with amyloid-beta using GM-CSF and IL-4 reduces amyloid burden and alters plaque morphology. <b>2006</b> , 23, 433-44	16
992	Anti-Abeta single-chain antibody delivery via adeno-associated virus for treatment of Alzheimer's disease. <b>2006</b> , 23, 502-11	79
991	The modular systems biology approach to investigate the control of apoptosis in Alzheimer's disease neurodegeneration. <b>2006</b> , 7 Suppl 1, S2	36
990	Insulin degrading enzyme is localized predominantly at the cell surface of polarized and unpolarized human cerebrovascular endothelial cell cultures. <b>2006</b> , 83, 1262-70	37
989	Early diagnostics and therapeutics for Alzheimer's disease--how early can we get there?. <b>2006</b> , 6, 1293-306	19
988	Alzheimer's disease. <b>2006</b> , 26, 499-506	45
987	Vaccine development for Alzheimer's disease. <b>2006</b> , 12, 4283-93	13
986	Changing the Course of Alzheimers Disease: Emerging Disease Modifying Therapies. <b>2006</b> , 2, 179-188	3
985	Role of toll-like receptor signalling in Abeta uptake and clearance. <b>2006</b> , 129, 3006-19	389
984	Has the amyloid cascade hypothesis for Alzheimer's disease been proved?. <b>2006</b> , 3, 71-3	194
983	Amplicons as vaccine vectors. <b>2006</b> , 6, 383-92	13
982	Immunotherapy for conformational diseases. <b>2006</b> , 12, 2569-85	20
981	HSV amplicons: neuro applications. <b>2006</b> , 6, 337-50	9
980	Brain inflammation, cholesterol, and glutamate as interconnected participants in the pathology of Alzheimer's disease. <b>2006</b> , 12, 719-38	28
979	The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. <b>2006</b> , 6, 597-608	96

978	Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease. <b>2006</b> , 20, 426-33		101
977	Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 39413-23	5-4	227
976	Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. <b>2006</b> , 318, 855-62		36
975	Effect of nonlinear wave-particle interaction on electron-cyclotron absorption. <b>2006</b> , 48, 1297-1310		3
974	Immunotherapeutic relief from persistent infections and amyloid disorders. <b>2006</b> , 66, S59-64		8
973	Brain and brawn: parallels in oxidative strength. <b>2006</b> , 66, S97-101		46
972	Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 4292-9	5-4	220
971	Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. <b>2006</b> , 26, 11437-41		38
970	Insights into the mechanisms of action of anti-Abeta antibodies in Alzheimer's disease mouse models. <b>2006</b> , 20, 2576-8		97
969	Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. <b>2006</b> , 103, 5048-53		123
968	Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety. <b>2006</b> , 103, 9619-24		58
967	Causes and Diagnosis of Alzheimers Disease: A Proteomics Approach. <b>2006</b> , 3, 81-112		2
966	Vaccination against C-terminal region of amyloid-beta peptide attenuates plaque deposition in prevention studies. <b>2006</b> , 16, 871-874		
965	Therapeutic approaches to Alzheimer's disease. <b>2006</b> , 129, 2840-55		257
964	Emerging therapeutics for Alzheimer's disease. <b>2006</b> , 6, 695-704		27
963	Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune response. <b>2006</b> , 26, 4717-28		133
962	Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. <b>2006</b> , 177, 2662-2670		43
961	Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. <b>2006</b> , 26, 5340-6		145

960	Immunization therapy in Alzheimer's disease. <b>2006</b> , 6, 653-9	6
959	Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humans. <b>2006</b> , 9, 77-84	55
958	Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. <b>2006</b> , 26, 365-71	61
957	Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 11436-45	54
956	Protein Misfolding, Aggregation, and Conformational Diseases. <b>2007</b> ,	13
955	Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid. <b>2007</b> , 27, 2654-62	42
954	Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. <b>2007</b> , 27, 9115-29	397
953	Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging. <b>2007</b> , 27, 1973-80	51
952	Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. <b>2007</b> , 27, 10957-68	246
951	Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. <b>2007</b> , 27, 13376-83	41
950	The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. <b>2007</b> , 320, 386-96	103
949	Immunotherapy as treatment for Alzheimer's disease. <b>2007</b> , 7, 1535-48	25
948	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. <b>2007</b> , 7, 473-85	36
947	Disease modifying approaches for Alzheimer's pathology. <b>2007</b> , 13, 1943-54	37
946	Novel Abeta immunogens: is shorter better?. <b>2007</b> , 4, 427-36	28
945	Advances on the understanding of the origins of synaptic pathology in AD. <b>2007</b> , 8, 486-508	28
944	Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?. <b>2007</b> , 4, 253-62	74
943	A 63-year-old man with headaches and behavioral deterioration. <b>2007</b> , 68, 782-7	14



942	Current therapeutic options for Alzheimer's disease. <b>2007</b> , 8, 550-8	42
941	Current experimental therapy for Alzheimer's disease. <b>2007</b> , 5, 127-34	10
940	Disrupting beta-amyloid aggregation for Alzheimer disease treatment. <b>2007</b> , 7, 115-26	143
939	Translational considerations for CNS gene therapy. <b>2007</b> , 7, 305-18	13
938	Neuronal damage in brain inflammation. <b>2007</b> , 64, 185-9	136
937	Clinical immunologic approaches for the treatment of Alzheimer's disease. <b>2007</b> , 16, 819-28	16
936	Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. <b>2007</b> , 64, 583-7	57
935	Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced beta-cell apoptosis in h-IAPP transgenic mice. <b>2007</b> , 56, 1324-32	152
934	Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. <b>2007</b> , 27, 6174-84	313
933	Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. <b>2007</b> , 18, 1490-6	169
932	Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 22376-86	5.4 83
931	Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. <b>2007</b> , 104, 2507-12	60
930	Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. <b>2007</b> , 104, 2495-500	185
929	Chapter 2 Alzheimer's Disease. <b>2007</b> , 33-58	1
928	Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice. <b>2007</b> , 27, 12721-31	81
927	Systemic and acquired immune responses in Alzheimer's disease. <b>2007</b> , 82, 205-33	72
926	Immunotherapeutic Approaches to Alzheimer's Disease. <b>2007</b> , 245-258	
925	Course of cerebral amyloid angiopathy-related inflammation. <b>2007</b> , 68, 1411-6	233

924	Atlas of Alzheimer's Disease. <b>2007</b> ,	6
923	Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice. <b>2007</b> , 104, 9810-5	130
922	[Progress in the studies of Alzheimer's disease]. <b>2007</b> , 96, 521-8	
921	One hundred years after the discovery of Alzheimer's disease. A turning point for therapy?. <i>Journal of Alzheimer's Disease</i> , <b>2007</b> , 12, 37-52	43 79
920	Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2007</b> , 11, 457-63	43 93
919	Clinical trials of amyloid-based therapies for Alzheimer's disease. <b>2007</b> , 12, 7-10	4
918	Mild Cognitive Impairment. <b>2007</b> ,	
917	Pharmacotherapy of Alzheimer disease. <b>2007</b> , 52, 620-9	20
916	Chapter 1 Amyloid and Amyloid-Like Protein Aggregates in Neurodegenerative Disease. <b>2007</b> , 30, 1-32	
915	ALZHEIMER'S DISEASE. <b>2007</b> , 13, 39-68	3
914	Antibody against C-terminal Abeta selectively elevates plasma Abeta. <b>2007</b> , 18, 293-6	15
913	Consent in Alzheimer's disease research: risk/benefit factors. <b>2007</b> , 34 Suppl 1, S27-31	8
912	Site-specific UBIt amyloid-beta vaccine for immunotherapy of Alzheimer's disease. <b>2007</b> , 25, 3041-52	64
911	Vessel ultrastructure in APP23 transgenic mice after passive anti-Abeta immunotherapy and subsequent intracerebral hemorrhage. <b>2007</b> , 28, 202-12	33
910	Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg mice. <b>2007</b> , 28, 813-23	52
909	Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. <b>2007</b> , 144, 950-60	88
908	Impact of amyloid imaging on drug development in Alzheimer's disease. <b>2007</b> , 34, 809-22	105
907	Microglial transplantation increases amyloid-beta clearance in Alzheimer model rats. <b>2007</b> , 581, 475-8	74

906 A Brief Introduction to the History of the [Amyloid Protein (A)] of Alzheimer's Disease. **2007**, 1-4

905 Abeta Peptide and Alzheimer's Disease. **2007**,

1

904 Pharmacological Mechanisms in Alzheimer's Therapeutics. **2007**,

1

903 Vaccination strategies for Alzheimer's disease: A new hope?. **2007**, 24, 107-19

13

902 Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. **2007**, 20, 947-56

377

901 Small molecule inhibitors of Abeta assembly. **2007**, 14, 185-97

59

900 Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. **2007**, 21, 2135-48

125

899 Amyloid imaging in vivo: implications for Alzheimer's disease management. **2007**, 1, 337-49

3

898 A neuroimmunologist's perspective on Alzheimer's disease therapy. **2007**, 7, 439-41

897 The Pathogenesis of Alzheimer's Disease: General Overview. **2007**, 3-29

1

896 Alzheimer's Disease. **2007**,

895 The Molecular Basis of Alzheimer's Disease. **2007**, 241-255

894 1. ??? (????????????????). **2007**, 38, 369-373

893 Diseases of protein misfolding. 113-131

892 The underestimated potential of the immune system in prevention of Alzheimer's disease pathology. **2007**, 29, 927-32

4

891 Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. **2007**, 62, 229-34

420

890 Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease. **2007**, 9, 88-98

37

889 Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease. **2007**, 112, 30-8

49

888	Molecular basis of Alzheimer's disease. <b>2007</b> , 41, 294-307	14
887	Immunology: Pimp my antibody. <b>2007</b> , 446, 964-6	7
886	Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. <b>2007</b> , 8, 101-12	3692
885	Insights into prion strains and neurotoxicity. <b>2007</b> , 8, 552-61	244
884	Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. <b>2008</b> , 18, 253-66	439
883	Deglycosylated anti-amyloid beta antibodies reduce microglial phagocytosis and cytokine production while retaining the capacity to induce amyloid beta sequestration. <b>2007</b> , 26, 2458-68	21
882	Monoclonal antibodies that target pathological assemblies of Abeta. <b>2007</b> , 100, 23-35	271
881	A beta oligomers - a decade of discovery. <b>2007</b> , 101, 1172-84	1609
880	In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. <b>2007</b> , 102, 420-33	71
879	Therapeutic approaches for prion and Alzheimer's diseases. <b>2007</b> , 274, 3784-98	32
878	Immunity and neuronal repair in the progression of Alzheimer's disease: a brief overview. <b>2007</b> , 42, 64-9	12
877	Pro-inflammatory conditions promote neuronal damage mediated by Amyloid Precursor Protein and decrease its phagocytosis and degradation by microglial cells in culture. <b>2007</b> , 26, 153-64	38
876	Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?. <b>2007</b> , 6, 373-8	145
875	Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimer's disease. <b>2007</b> , 1097, 239-58	16
874	Virus-like particles: flexible platforms for vaccine development. <b>2007</b> , 6, 381-90	242
873	Thermodynamic studies on the interaction of antibodies with beta-amyloid peptide. <b>2007</b> , 111, 1238-43	17
872	[Does youth mean vigorous and age, feeble biological repair mechanisms?]. <b>2007</b> , 78, 1399-406	
871	Research into neurodegenerative disease: an entangled web of mice and men. <i>Acta Neuropathologica</i> , <b>2008</b> , 115, 1-4	14.3 5

870	Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. <i>Neurotherapeutics</i> , <b>2008</b> , 5, 415-20	6.4	52
869	Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. <b>2008</b> , 65, 2574-85		128
868	Amyloid plaque imaging in vivo: current achievement and future prospects. <b>2008</b> , 35 Suppl 1, S46-50		60
867	[Current immune therapy for Alzheimer's disease]. <b>2008</b> , 79, 832-5		3
866	[Innovative treatment approaches for Alzheimer's disease. Immunotherapy]. <b>2008</b> , 79 Suppl 3, 149-57; quiz 158		
865	Therapeutic strategies for Alzheimer's disease. <b>2008</b> , 37, 171-86		102
864	Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. <i>Acta Neuropathologica</i> , <b>2008</b> , 115, 497-507	14.3	88
863	Neurochemical dementia diagnostics: State of the art and research perspectives. <b>2008</b> , 8, 1292-301		42
862	Multiple sclerosis and Alzheimer's disease. <b>2008</b> , 63, 174-83		82
861	Detection of isolated cerebrovascular beta-amyloid with Pittsburgh compound B. <b>2008</b> , 64, 587-91		77
860	Failure of elimination of amyloid- $\beta$ from the brain in Alzheimer's disease. <b>2008</b> , 12, 6-10		
859	Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases. <b>2008</b> , 7 Suppl 1, 12-27		13
858	Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques. <b>2008</b> , 7 Suppl 1, 67-82		62
857	Can the immune system be harnessed to repair the CNS?. <b>2008</b> , 9, 481-93		222
856	Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. <i>Nature Medicine</i> , <b>2008</b> , 14, 681-7	50.5	353
855	The adult human brain in preclinical drug development. <b>2008</b> , 7, 659-66		94
854	Developing preventive therapies for chronic diseases: lessons learned from Alzheimer's disease. <b>2007</b> , 65, S239-43		29
853	The role of the immune system in clearance of Abeta from the brain. <b>2008</b> , 18, 267-78		80

852	Antibody-based approaches in Alzheimer's research: safety, pharmacokinetics, metabolism, and analytical tools. <b>2008</b> , 104, 859-74	55
851	Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-beta antibody attenuates pathologies in an age-related macular degeneration mouse model. <b>2008</b> , 48, 339-45	81
850	Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid beta peptides. <b>2008</b> , 9, 25	17
849	Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. <b>2008</b> , 7, 391-7	35
848	Plasma antibodies to Abeta40 and Abeta42 in patients with Alzheimer's disease and normal controls. <b>2008</b> , 1219, 169-79	23
847	Amyloid-beta immunisation for Alzheimer's disease. <b>2008</b> , 7, 805-11	122
846	Biomarkers for early diagnosis of Alzheimer disease: 'ALzheimer ASsociated gene'--a new blood biomarker?. <b>2008</b> , 12, 1094-117	37
845	Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease. <b>2008</b> , 12, 762-80	164
844	Parenchymal and vascular Abeta-deposition and its effects on the degeneration of neurons and cognition in Alzheimer's disease. <b>2008</b> , 12, 1848-62	90
843	Pharmacotherapeutic targets in Alzheimer's disease. <b>2009</b> , 13, 61-86	44
842	Mutant amyloid-beta-sensitized dendritic cells as Alzheimer's disease vaccine. <b>2008</b> , 200, 1-10	12
841	DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. <b>2008</b> , 205, 57-63	27
840	A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection. <b>2008</b> , 131, 113-20	65
839	CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation. <b>2008</b> , 29, 336-53	22
838	Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. <b>2008</b> , 3, e1376	264
837	Neuropathology of Alzheimer's disease. <b>2008</b> , 89, 233-43	33
836	Neurodegenerative Diseases. <b>2008</b> , 565-588	0
835	Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response. <b>2008</b> , 272, 87-98	33

834	Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. <i>Journal of Neuroinflammation</i> , <b>2008</b> , 5, 42	10.1	30
833	Clinical immunotherapy trials in Alzheimer's disease. <b>2008</b> , 5, 177-183		3
832	Neuroinflammation in Early Stages of Alzheimer's Disease and Parkinson's Disease. <b>2008</b> , 113-121		
831	Advances in Alzheimer's and Parkinson's Disease. <b>2008</b> ,		
830	Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease. <b>2008</b> , 93-157		6
829	Detection of amyloid beta protein in the urine of Alzheimer's disease patients and healthy individuals. <b>2008</b> , 435, 126-30		18
828	Enhanced Th2 immunity after DNA prime-protein boost immunization with amyloid beta (1-42) plus CpG oligodeoxynucleotides in aged rats. <b>2008</b> , 436, 219-22		15
827	Hippocampal hypometabolism predicts cognitive decline from normal aging. <b>2008</b> , 29, 676-92		239
826	Opposite patterns of age-associated changes in neurons and glial cells of the thalamus of human brain. <b>2008</b> , 29, 926-36		14
825	Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. <b>2008</b> , 20, 267-75		133
824	Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. <b>2008</b> , 17, 423-39		97
823	Current approaches in the treatment of Alzheimer's disease. <b>2008</b> , 62, 199-207		118
822	Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. <b>2008</b> , 173, 483-93		26
821	Disease-modifying therapies in Alzheimer's disease. <b>2008</b> , 4, 65-79		103
820	The amyloid cascade hypothesis. <b>2008</b> , 4, 176-8		74
819	Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. <b>2008</b> , 372, 216-23		1140
818	Active and passive immunotherapy for neurodegenerative disorders. <b>2008</b> , 31, 175-93		202
817	Preventing Alzheimer's disease : separating fact from fiction. <b>2008</b> , 22, 887-902		13

816	Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. <b>2009</b> , 132, 1078-92		179
815	Perspectives of Alzheimer's disease treatments. <b>2008</b> , 89, 273-90		1
814	Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis. <b>2008</b> , 5, 194-6		89
813	Immunotherapy reduces vascular amyloid-beta in PDAPP mice. <b>2008</b> , 28, 6787-93		103
812	Antibody capture of soluble Abeta does not reduce cortical Abeta amyloidosis in the PDAPP mouse. <b>2008</b> , 5, 65-71		62
811	Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease. <b>2008</b> , 14, 3231-46		94
810	Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. <b>2008</b> , 89, 1533-1544		48
809	Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. <b>2008</b> , 131, 3299-310		236
808	Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 22550-6	5.4	16
807	Autoantibody-catalyzed hydrolysis of amyloid beta peptide. <i>Journal of Biological Chemistry</i> , <b>2008</b> , 283, 4714-22	5.4	58
806	A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. <b>2008</b> , 28, 3555-66		90
805	Complementary distributions of amyloid-beta and neprilysin in the brains of dogs and cats. <b>2008</b> , 45, 455-66		9
804	The coming of age of virus-like particle vaccines. <b>2008</b> , 389, 521-36		266
803	IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1-42) by rat primary type 2 microglia. <b>2008</b> , 181, 6503-13		111
802	Memory loss in Alzheimer's disease: implications for development of therapeutics. <b>2008</b> , 8, 1879-91		97
801	Non-cholinergic drug development for Alzheimer's disease. <b>2008</b> , 3, 745-60		3
800	Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-beta and interleukin-4. <b>2008</b> , 16, 845-53		48
799	DNA vaccine therapy for Alzheimer's disease: present status and future direction. <b>2008</b> , 11, 301-8		13



798	Vascular diseases. <b>2008</b> , 121-240		6
797	The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 15, 685-707	4.3	136
796	Alzheimer's disease. <b>2008</b> , 199-228		6
795	Inflammatory aspects of Alzheimer disease and other neurodegenerative disorders. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 13, 359-69	4.3	192
794	Nonviral DNA vaccination augments microglial phagocytosis of beta-amyloid deposits as a major clearance pathway in an Alzheimer disease mouse model. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2008</b> , 67, 1063-71	3.1	12
793	Alzheimer's Disease Research: Progress and Promises. <b>2008</b> , 13, 10-14		1
792	FDG and amyloid positron emission tomography. <b>2008</b> , 13, 21-4		1
791	Current state of immunotherapy for Alzheimer's disease. <b>2008</b> , 13, 39-41		11
790	Development and characterization of a TAPIR-like mouse monoclonal antibody to amyloid-beta. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 14, 161-73	4.3	10
789	Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 15, 555-69	4.3	85
788	Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 15, 157-68	4.3	94
787	Immunotherapy for Alzheimer's disease: harnessing our knowledge of T cell biology using a cholesterol-fed rabbit model. <i>Journal of Alzheimer's Disease</i> , <b>2008</b> , 15, 657-71	4.3	6
786	Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. <b>2008</b> , 1, 29-39		32
785	Present and prospective clinical therapeutic regimens for Alzheimer's disease. <b>2008</b> , 4, 765-77		17
784	Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. <b>2008</b> , 3, e2124		87
783	The PPAR-gamma Agonist 15-Deoxy-Delta-Prostaglandin J(2) Attenuates Microglial Production of IL-12 Family Cytokines: Potential Relevance to Alzheimer's Disease. <b>2008</b> , 2008, 349185		16
782	Taking the next steps in the treatment of Alzheimer's disease: disease-modifying agents. <b>2008</b> , 13, 11-4		
781	Cerebral amyloid angiopathy. 41-57		1

780	Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine. <i>Journal of Alzheimer's Disease</i> , <b>2009</b> , 18, 961-72	4-3	13
779	Novel Pharmacotherapies for Alzheimer's Disease. <b>2009</b> , 52, 1059		9
778	Amyloid: Vascular and Parenchymal. <b>2009</b> , 355-362		1
777	The endocannabinoid system in neuropathological states. <b>2009</b> , 21, 172-80		24
776	Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice. <b>2009</b> , 106, 4501-6		102
775	Molecular basis of catalytic chamber-assisted unfolding and cleavage of human insulin by human insulin-degrading enzyme. <i>Journal of Biological Chemistry</i> , <b>2009</b> , 284, 14177-88	5-4	56
774	Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice. <b>2009</b> , 29, 14108-19		53
773	A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. <b>2009</b> , 73, 2061-70		554
772	Recent advance in immunotherapies for Alzheimer disease: with special reference to DNA vaccination. <b>2009</b> , 5, 373-80		9
771	Immunotherapy for Alzheimer's disease. <b>2009</b> , 1, 461-9		4
770	Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. <b>2009</b> , 66, 60-7		130
769	Anti-amyloid treatments in Alzheimer's disease. <b>2009</b> , 4, 143-8		8
768	Is passive immunization for Alzheimer's disease 'alive and well' or 'dead and buried'?. <b>2009</b> , 9, 481-91		22
767	Neuro-transmitters in the central nervous system & their implication in learning and memory processes. <b>2009</b> , 16, 796-840		63
766	Microglial activation in Alzheimer's disease. <b>2009</b> , 6, 554-63		67
765	Adoptive transfer of T lymphocytes sensitized against the prion protein attenuates prion invasion in scrapie-infected mice. <b>2009</b> , 183, 6619-28		9
764	Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. <b>2009</b> , 182, 7613-24		33
763	Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. <b>2009</b> , 6, 144-51		207

762	Novel therapeutic modalities to address nondrugable protein interaction targets. <b>2009</b> , 34, 142-58		31
761	Severely dystrophic axons at amyloid plaques remain continuous and connected to viable cell bodies. <b>2009</b> , 132, 402-16		119
760	Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. <b>2009</b> , 6, 446-50		73
759	Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2009</b> , 18, 131-9	4.3	218
758	Small molecule blockers of the Alzheimer Abeta calcium channel potentially protect neurons from Abeta cytotoxicity. <b>2009</b> , 106, 3348-53		93
757	A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. <b>2009</b> , 35, 359-67		262
756	Alzheimer's-associated Abeta oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. <b>2009</b> , 240, 189-97		105
755	Neuronal death in Alzheimer's disease and therapeutic opportunities. <b>2009</b> , 13, 4329-48		71
754	Monitoring the amyloid beta-peptide in vivo--caveat emptor. <b>2009</b> , 14, 241-51		9
753	Neuroinflammation in Parkinson's disease: a target for neuroprotection?. <b>2009</b> , 8, 382-97		1326
752	Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden. <b>2009</b> , 65, 24-31		104
751	Development of vaccination approaches for the treatment of neurological diseases. <b>2009</b> , 515, 4-14		11
750	Alzheimer â Mechanismen und therapeutische Ansätze. Warum wir im Alter dement werden. <b>2009</b> , 39, 92-100		
749	Promoting alpha-secretase cleavage of beta-amyloid with engineered proteolytic antibody fragments. <b>2009</b> , 25, 1054-63		9
748	Lymphatic drainage of the brain and the pathophysiology of neurological disease. <i>Acta Neuropathologica</i> , <b>2009</b> , 117, 1-14	14.3	367
747	Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. <i>Acta Neuropathologica</i> , <b>2009</b> , 118, 87-102	14.3	226
746	The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses. <b>2009</b> , 30, 5869-76		26
745	Alzheimer's disease and blood-brain barrier function-Why have anti-beta-amyloid therapies failed to prevent dementia progression?. <b>2009</b> , 33, 1099-108		57

744	Intramembranous fragment of amyloid-beta: A potential immunogen for Alzheimer's disease immunotherapy. <b>2009</b> , 34, 1889-95	
743	Chaperone-like antibodies in neurodegenerative tauopathies: implication for immunotherapy. <b>2009</b> , 29, 793-8	17
742	An update on treatment and prevention strategies for Alzheimer's disease. <b>2009</b> , 9, 368-76	32
741	Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases. <b>2009</b> , 4, 298-308	7
740	Imaging microglial activation during neuroinflammation and Alzheimer's disease. <b>2009</b> , 4, 227-43	123
739	Inflammation and microglia actions in Alzheimer's disease. <b>2009</b> , 4, 380-8	41
738	Development of AFFITOPE vaccines for Alzheimer's disease (AD)--from concept to clinical testing. <b>2009</b> , 13, 264-7	100
737	Does neuroinflammation fan the flame in neurodegenerative diseases?. <b>2009</b> , 4, 47	505
736	Immunization in Alzheimer's disease: naïve hope or realistic clinical potential?. <b>2009</b> , 14, 239-51	30
735	Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. <b>2009</b> , 14, 469-86	179
734	Brain banking: opportunities, challenges and meaning for the future. <b>2009</b> , 10, 70-8	90
733	The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. <b>2009</b> , 110, 1129-34	585
732	Prefilament tau species as potential targets for immunotherapy for Alzheimer disease and related disorders. <b>2009</b> , 21, 359-63	44
731	Dementias. <b>2009</b> , 215-257	
730	Current Hypotheses and Research Milestones in Alzheimer's Disease. <b>2009</b> ,	1
729	1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. <i>Journal of Alzheimer's Disease</i> , <b>2009</b> , 17, 703-17	43 149
728	In vivo target validation using gene invalidation, RNA interference and protein functional knockout models: it is the time to combine. <b>2009</b> , 9, 669-76	18
727	Prevention of age-associated dementia. <b>2009</b> , 80, 315-25	23

726	Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model. <b>2009</b> , 382, 149-52	6
725	Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. <b>2009</b> , 30, 364-76	46
724	Insulin rescues amyloid beta-induced impairment of hippocampal long-term potentiation. <b>2009</b> , 30, 377-87	69
723	Dystrophic neurites in TgCRND8 and Tg2576 mice mimic human pathological brain aging. <b>2009</b> , 30, 864-74	36
722	PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. <b>2009</b> , 30, 1217-26	106
721	Expression, purification, and characterization of recombinant human beta-amyloid42 peptide in Escherichia coli. <b>2009</b> , 64, 55-62	25
720	When should drug treatment be started for people with dementia?. <b>2009</b> , 62, 230-4	7
719	Immunogenic, antigenic, fibrillogenic and inflammatory properties of new simplified beta-amyloid peptides. <b>2009</b> , 46, 2524-32	2
718	Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. <b>2009</b> , 30, 1936-48	102
717	Aging of the Brain and Alzheimer's Disease. <b>2009</b> , 187-195	3
716	Antibodies and the Blood-Brain Barrier. 483-502	2
715	Targeting the JAK2/STAT3 axis in Alzheimer's disease. <b>2009</b> , 13, 1155-67	72
714	Immune responses to herpesviral vectors. <b>2009</b> , 20, 434-41	9
713	Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. <b>2009</b> , 1, 6	97
712	Developing novel immunogens for a safe and effective Alzheimer's disease vaccine. <b>2009</b> , 175, 83-93	68
711	Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. <b>2009</b> , 5, 340-7	83
710	Alzheimer's disease drug development and the problem of the blood-brain barrier. <b>2009</b> , 5, 427-32	123
709	Biological marker candidates of Alzheimer's disease in blood, plasma, and serum. <b>2009</b> , 15, 358-74	113

708 Complexity of microglial activation state: can modifying microglial activation treat Alzheimer's disease?. **2009**, 4, 137-139

707 6. Recent Progress of Alzheimer's Dementia. **2009**, 98, 2305-2311

1

706 Animal models of dementia. 131-141

705 Alzheimer's Disease and Other Dementias (Including Pseudodementias). 543-615

28

704 [Immunotherapy of Alzheimer's disease by Abeta vaccination]. **2009**, 134, 59-63

703 AD vaccines: conclusions and future directions. **2009**, 8, 160-6

10

702 Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. **2009**, 8, 144-59

30

701 Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. **2009**, 8, 50-64

69

700 Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. **2009**, 8, 128-43

20

699 Quantitative and mechanistic studies of Abeta immunotherapy. **2009**, 8, 31-49

39

698 Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial. **2009**, 8, 88-97

31

697 Immunotherapy in a natural model of Abeta pathogenesis: the aging beagle. **2009**, 8, 98-113

10

696 Alternative Abeta immunotherapy approaches for Alzheimer's disease. **2009**, 8, 114-27

34

695 Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid- $\beta$  clearance in Alzheimer's disease. **2010**, 7, 578-90

24

694 Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. **2010**, 33, 67-73

147

693 [Treatment of Alzheimer's disease and future approaches]. **2010**, 65, 429-37

1

692 Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. *Journal of Alzheimer's Disease*, **2010**, 21, 1-14

4.3 164

691 [Current status of Alzheimer's disease immunotherapy and pharmacologic effect of BAN2401]. **2010**, 136, 21-5

1

690	Immunization therapy for Alzheimer disease: a comprehensive review of active immunization strategies. <b>2010</b> , 220, 95-106		54
689	Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease. <b>2010</b> , 329-404		
688	Current therapeutic targets for the treatment of Alzheimer's disease. <b>2010</b> , 10, 711-28		83
687	Galantamine-induced amyloid- $\beta$ clearance mediated via stimulation of microglial nicotinic acetylcholine receptors. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 40180-91	5-4	115
686	Vaccination as a therapeutic approach to Alzheimer's disease. <b>2010</b> , 77, 17-31		37
685	Current treatment and recent clinical research in Alzheimer's disease. <b>2010</b> , 77, 3-16		55
684	Chapter 4: The Bimodal Features of Butyrylcholinesterase in Cholinergic Neurotransmission and Amyloid Suppression. <b>2010</b> , 59-93		
683	Alzheimer disease. <b>2010</b> , 56, 484-546		290
682	Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2010</b> , 120, 13-20	14-3	67
681	Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. <i>Acta Neuropathologica</i> , <b>2010</b> , 120, 369-84	14-3	105
680	Novel therapeutic approach for Alzheimer's disease by removing amyloid beta protein from the brain with an extracorporeal removal system. <b>2010</b> , 13, 31-7		21
679	Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. <b>2010</b> , 214, 201-18		35
678	Macrophages in Alzheimer's disease: the blood-borne identity. <b>2010</b> , 117, 961-70		72
677	Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications. <b>2010</b> , 32, 365-84		11
676	Virus-like peptide vaccines against Abeta N-terminal or C-terminal domains reduce amyloid deposition in APP transgenic mice without addition of adjuvant. <b>2010</b> , 5, 133-42		11
675	Specific and efficient anti-A $\beta$ 2 antibodies induced by sixteen tandem repeats of A $\beta$ . <b>2010</b> , 227, 18-25		6
674	Enoxaparin treatment administered at both early and late stages of amyloid $\beta$ deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain A $\beta$ levels. <b>2010</b> , 40, 340-7		55
673	Simvastatin enhances immune responses to A $\beta$ vaccination and attenuates vaccination-induced behavioral alterations. <b>2010</b> , 1356, 102-11		6

672	Immunization against angiotensins for the treatment of hypertension. <b>2010</b> , 134, 89-95		29
671	Microglia in the degenerating brain are capable of phagocytosis of beads and of apoptotic cells, but do not efficiently remove PrPSc, even upon LPS stimulation. <b>2010</b> , 58, 2017-30		77
670	Alzheimer Disease: Protein Misfolding, Model Systems, and Experimental Therapeutics. <b>2010</b> , 231-258		1
669	Current and Future Therapies for Alzheimer Disease. <b>2010</b> , 711-774		
668	APP transgenic mice: the effect of active and passive immunotherapy in cognitive tasks. <b>2010</b> , 34, 487-99		16
667	Vaccines against non-communicable diseases. <b>2010</b> , 22, 391-6		18
666	The biochemical aftermath of anti-amyloid immunotherapy. <b>2010</b> , 5, 39		32
665	The endocannabinoid system as a target for the treatment of neurodegenerative disease. <b>2010</b> , 160, 480-98		118
664	Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. <b>2010</b> , 113, 1188-99		139
663	Therapeutic removal of amyloid deposits in cutaneous amyloidosis by localised intra-lesional injections of anti-amyloid antibodies. <b>2010</b> , 19, 904-11		9
662	DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. <b>2010</b> , 17, 261-71		38
661	The benefits and limitations of animal models for translational research in neurodegenerative diseases. <i>Nature Medicine</i> , <b>2010</b> , 16, 1210-4	50.5	248
660	Translating research on brain aging into public health: a new type of immunotherapy for Alzheimer's disease. <b>2010</b> , 68 Suppl 2, S128-34		2
659	Mary S. Easton Center of Alzheimer's Disease Research at UCLA: advancing the therapeutic imperative. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 19, 375-88	4.3	2
658	The central role of T-cell memory in Alzheimer's disease vaccination. <b>2010</b> , 1, 5		
657	Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 19, 885-94	4.3	92
656	Amyloid-beta immunotherapy for Alzheimer's disease. <b>2010</b> , 9, 197-206		61
655	The monomer state of beta-amyloid: where the Alzheimer's disease protein meets physiology. <b>2010</b> , 21, 83-93		60



654	The older brain, inflammation, vaccination and the prevention of dementia. <b>2010</b> , 20, 288-308		
653	Structural correlates of antibodies associated with acute reversal of amyloid beta-related behavioral deficits in a mouse model of Alzheimer disease. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 3417-27	5.4	29
652	A single ascending dose study of bapineuzumab in patients with Alzheimer disease. <b>2010</b> , 24, 198-203		108
651	Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. <b>2010</b> , 30, 16559-66		227
650	Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease. <b>2010</b> , 6, 931-5		31
649	Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials. <b>2010</b> , 4, 81-9		20
648	Are we getting to grips with Alzheimer's disease at last?. <b>2010</b> , 133, 1297-9		7
647	Targeted hydrolysis of Beta-amyloid with engineered antibody fragment. <b>2010</b> , 7, 214-22		10
646	Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. <b>2010</b> , 19, 2947-57		67
645	Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. <b>2010</b> , 133, 1312-27		118
644	Simplified Amyloid peptides for safer Alzheimer's vaccines development. <b>2010</b> , 6, 936-47		2
643	AFFITOME <sup>®</sup> technology in neurodegenerative diseases: the doubling advantage. <b>2010</b> , 6, 948-52		36
642	Virus-like particle based vaccines for Alzheimer disease. <b>2010</b> , 6, 926-930		22
641	Immunotherapy for prion diseases: opportunities and obstacles. <b>2010</b> , 2, 269-82		21
640	Case records of the Massachusetts General Hospital. Case 22-2010. An 87-year-old woman with dementia and a seizure. <b>2010</b> , 363, 373-81		9
639	Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. <b>2010</b> , 18, 1471-81		60
638	Clinical applications of a peptide-based vaccine for glioblastoma. <b>2010</b> , 21, 95-109		15
637	Microglia in neurodegenerative disease. <b>2010</b> , 6, 193-201		1119

636	Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. <b>2010</b> , 70, 513-28	81
635	Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. <b>2010</b> , 1207, 58-70	48
634	Engineered proteolytic nanobodies reduce Abeta burden and ameliorate Abeta-induced cytotoxicity. <b>2010</b> , 49, 4501-8	15
633	Inflammation in transgenic mouse models of neurodegenerative disorders. <b>2010</b> , 1802, 889-902	74
632	Mouse models in neurological disorders: applications of non-invasive imaging. <b>2010</b> , 1802, 819-39	37
631	Murine models of Alzheimer's disease and their use in developing immunotherapies. <b>2010</b> , 1802, 847-59	55
630	Intramuscular delivery of a single chain antibody gene prevents brain A $\beta$ deposition and cognitive impairment in a mouse model of Alzheimer's disease. <b>2010</b> , 24, 1281-93	33
629	Design and development of non-fibrillar amyloid beta as a potential Alzheimer vaccine. <b>2010</b> , 394, 393-7	4
628	Reduction of amyloid beta-peptide accumulation in Tg2576 transgenic mice by oral vaccination. <b>2010</b> , 399, 593-9	16
627	ADDLs and the signaling web that leads to Alzheimer's disease. <b>2010</b> , 59, 230-42	90
626	Valproic acid enhances microglial phagocytosis of amyloid-beta(1-42). <b>2010</b> , 169, 505-15	43
625	Targeting Abeta and tau in Alzheimer's disease, an early interim report. <b>2010</b> , 223, 252-66	68
624	Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. <b>2010</b> , 224, 472-85	142
623	Suppressed accumulation of cerebral amyloid {beta} peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. <b>2010</b> , 177, 346-54	49
622	The role of animal models in advancing amyloid-beta immunotherapy to the clinic. <b>2010</b> , 2, 22	
621	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. <b>2010</b> , 2, 1	142
620	Bapineuzumab. <b>2010</b> , 10, 1121-30	70
619	Low concentrations of anti-A $\beta$ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. <b>2010</b> , 21, 1569-76	7

618	Antibody-based therapy in Alzheimer's disease. <b>2011</b> , 11, 343-57	49
617	Brain microbleeds and Alzheimer's disease: innocent observation or key player?. <b>2011</b> , 134, 335-44	235
616	Induction of methionine-sulfoxide reductases protects neurons from amyloid $\beta$ protein insults in vitro and in vivo. <b>2011</b> , 50, 10687-97	42
615	Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential. <b>2011</b> , 15, 83-102	24
614	Experimental models of HD and reflection on therapeutic strategies. <b>2011</b> , 98, 419-81	14
613	The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. <b>2011</b> , 10, 698-712	1402
612	Animal Models of Dementia. <b>2011</b> ,	7
611	Solanezumab for Alzheimer's disease. <b>2011</b> , 11, 787-98	35
610	Alzheimer's Disease. <b>2011</b> , 1-91	7
609	Genetics of Alzheimer's disease: new evidences for an old hypothesis?. <b>2011</b> , 21, 295-301	94
608	Anti-amnesic and neuroprotective actions of the sigma-1 receptor agonist (-)-MR22 in rats with selective cholinergic lesion and amyloid infusion. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 24, 569-86	43 42
607	Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. <b>2011</b> , 25, 997-1019	141
606	Intranasal inoculation with an adenovirus vaccine encoding ten repeats of A $\beta$ -10 induces Th2 immune response against amyloid- $\beta$ in wild-type mouse. <b>2011</b> , 505, 128-33	5
605	Inhibiting $\beta$ secretase activity in Alzheimer's disease cell models with single-chain antibodies specifically targeting APP. <b>2011</b> , 405, 436-47	35
604	Identification of the shortest A $\beta$ peptide generating highly specific antibodies against the C-terminal end of amyloid- $\beta$ . <b>2011</b> , 29, 3260-9	13
603	Mucosal immunotherapy in an Alzheimer mouse model by recombinant Sendai virus vector carrying A $\beta$ -43/IL-10 cDNA. <b>2011</b> , 29, 7474-82	7
602	Wheat germ agglutinin enhanced cerebral uptake of anti-A $\beta$ antibody after intranasal administration in 5XFAD mice. <b>2011</b> , 29, 7631-7	8
601	Short amyloid-beta immunogens show strong immunogenicity and avoid stimulating pro-inflammatory pathways in bone marrow-derived dendritic cells from C57BL/6J mice in vitro. <b>2011</b> , 32, 1617-25	7

600	Novel insights for the treatment of Alzheimer's disease. <b>2011</b> , 35, 373-9	63
599	Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. <b>2011</b> , 7, 367-85	364
598	Assessment of non-viral amyloid- $\beta$ DNA vaccines on amyloid- $\beta$ reduction and safety in rhesus monkeys. <i>Journal of Alzheimer's Disease</i> , <b>2010</b> , 22, 1351-61	4.3 9
597	Rational Therapeutics for Alzheimer's Disease and Other Dementias. <b>2011</b> , 301-311	
596	Cerebral microbleeds in healthy populations. 79-86	1
595	Cerebral microbleeds in relation to cerebral amyloid angiopathy. 109-116	
594	Chronic intranasal treatment with an anti-A $\beta$ (30-42) scFv antibody ameliorates amyloid pathology in a transgenic mouse model of Alzheimer's disease. <b>2011</b> , 6, e18296	55
593	Alzheimer's disease: review of emerging treatment role for intravenous immunoglobulins. <b>2011</b> , 3, 67-73	6
592	Future targeted disease modifying drugs for Alzheimer's disease. <b>2011</b> , 6, 65-76	
591	Experimental and clinical application of plasmid DNA in the field of central nervous diseases. <b>2011</b> , 11, 491-500	24
590	Alzheimer's disease vaccines: promises and pitfalls. <b>2011</b> , 1, 969-988	1
589	Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials. <b>2011</b> , 17, 508-20	44
588	Determination of spatial and temporal distribution of microglia by 230nm-high-resolution, high-throughput automated analysis reveals different amyloid plaque populations in an APP/PS1 mouse model of Alzheimer's disease. <b>2011</b> , 8, 781-8	24
587	Pharmacological treatment of Alzheimer disease. <b>2011</b> , 56, 579-88	67
586	Gene therapy for Parkinson's and Alzheimer's diseases: from the bench to clinical trials. <b>2011</b> , 17, 3434-45	13
585	Tau as a therapeutic target for Alzheimer's disease. <b>2011</b> , 8, 666-77	50
584	An anti-A $\beta$ amyloid $\beta$ single-chain variable fragment prevents amyloid fibril formation and cytotoxicity by withdrawing A $\beta$ oligomers from the amyloid pathway. <b>2011</b> , 437, 25-34	32
583	Anti-Amyloid- $\beta$ Single-Chain Antibody Brain Delivery Via AAV Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer's Disease Mouse Model. <i>Journal of Alzheimer's Disease</i> , <b>2011</b> , 27, 23-38	4.3 31

- 582 [Dementia: progress in diagnosis and treatment; Topics, III. Treatments; 2. Pharmacological treatment of dementia]. **2011**, 100, 2134-45
- 581 Dendritic cells regulate amyloid- $\beta$ -specific T-cell entry into the brain: the role of perivascular amyloid- $\beta$ . *Journal of Alzheimer's Disease*, **2011**, 27, 99-111 4.3 20
- 580 Review: sporadic cerebral amyloid angiopathy. **2011**, 37, 75-93 232
- 579 Microglial alterations in human Alzheimer's disease following A $\beta$ 2 immunization. **2011**, 37, 513-24 72
- 578 Immunotherapy for Alzheimer's disease. **2011**, 269, 54-63 122
- 577 Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. **2011**, 118, 658-67 232
- 576 Anti-amyloid precursor protein immunoglobulins inhibit amyloid- $\beta$  production by steric hindrance. **2011**, 278, 167-78 6
- 575 CCR2/CCL2-mediated inflammation protects photoreceptor cells from amyloid- $\beta$ -induced apoptosis. **2011**, 42, 55-72 24
- 574 Therapeutic applications of antibodies in non-infectious neurodegenerative diseases. **2011**, 28, 511-7 7
- 573 Inflammation and gliosis in neurological diseases--clinical implications. **2011**, 231, 78-85 64
- 572 Improving memory and decreasing cognitive impairment in Tg-APPswe/PSEN1dE9 mice with A $\beta$ -10 repeat fragment plasmid by reducing A $\beta$  deposition and inflammatory response. **2011**, 1400, 112-24 7
- 571 Stages of granulovacuolar degeneration: their relation to Alzheimer's disease and chronic stress response. *Acta Neuropathologica*, **2011**, 122, 577-89 14.3 73
- 570 Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease. **2011**, 118, 747-52 80
- 569 Aberrant protein structure and diseases of the brain. **2011**, 180, 15-22 8
- 568 The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. **2011**, 9, 127 10
- 567 Cerebral amyloid angiopathy-related inflammation presenting with steroid-responsive higher brain dysfunction: case report and review of the literature. *Journal of Neuroinflammation*, **2011**, 8, 116 10.1 34
- 566 T cell mediated cerebral hemorrhages and microhemorrhages during passive A $\beta$  immunization in APPPS1 transgenic mice. **2011**, 6, 22 11
- 565 Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design. **2011**, 3, 174-196 155

564	Cerebral amyloid angiopathy in the elderly. <b>2011</b> , 70, 871-80	367
563	A 60-year-old woman with headache, confusion, and hallucinations. <b>2011</b> , 63, 1486-94	6
562	Therapeutic potential of vaccines for Alzheimer's disease. <b>2011</b> , 3, 287-98	15
561	Therapeutic interventions targeting Beta amyloid pathogenesis in an aging dog model. <b>2011</b> , 9, 651-61	14
560	Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. <b>2011</b> , 8, 659-65	56
559	South Wales joint neuroscience meeting, Bridgend, 29 April 2010: a 66-year-old man who suddenly couldn't drive. <b>2011</b> , 11, 153-9	
558	A highly specific antibody response after protein prime-peptide boost immunization with Eppin/B-cell epitope in mice. <b>2011</b> , 7, 849-55	5
557	Animal models for neural diseases. <b>2011</b> , 39, 167-9	7
556	Anti-amyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. <b>2011</b> , 108, E279-87	152
555	Alzheimer's disease: a review of recent developments. <b>2011</b> , 10, 73-9	14
554	The second-generation active A $\beta$ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. <b>2011</b> , 31, 9323-31	138
553	Molecular mechanisms and therapeutic application of NSAIDs and derived compounds in Alzheimer's disease. <b>2011</b> , 8, 115-31	39
552	Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. <b>2011</b> , 31, 4124-36	81
551	Cerebral amyloid angiopathy related inflammation: three case reports and a review. <b>2011</b> , 82, 20-6	128
550	MHC-independent genetic factors control the magnitude of CD4+ T cell responses to amyloid- $\beta$ peptide in mice through regulatory T cell-mediated inhibition. <b>2011</b> , 187, 4492-500	15
549	Longitudinal modeling of frontal cognition in APOE $\epsilon$ homozygotes, heterozygotes, and noncarriers. <b>2011</b> , 76, 1383-8	67
548	Neutralization of soluble, synaptotoxic amyloid $\beta$ species by antibodies is epitope specific. <b>2012</b> , 32, 2696-702	55
547	Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1. <b>2012</b> , 8, e1002918	100

546	Postmortem findings in a patient with cerebral amyloid angiopathy actively treated with corticosteroid. <b>2012</b> , 19, 47-52		8
545	Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. <b>2012</b> , 64, 27-81		66
544	The animal models of dementia and Alzheimer's disease for pre-clinical testing and clinical translation. <b>2012</b> , 9, 1010-29		31
543	Lifelong management of amyloid-beta metabolism to prevent Alzheimer's disease. <b>2012</b> , 367, 864-6		31
542	Jekyll and Hide: The two faces of amyloid $\beta$ <b>2012</b> , 5, 405-7		3
541	Convection-enhanced delivery of neprilysin: a novel amyloid- $\beta$ -degrading therapeutic strategy. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 32, 43-56	4-3	36
540	Soluble amyloid precursor protein 770 is released from inflamed endothelial cells and activated platelets: a novel biomarker for acute coronary syndrome. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 40817-25	5-4	37
539	Sporadic cerebral amyloid angiopathy revisited: recent insights into pathophysiology and clinical spectrum. <b>2012</b> , 83, 124-37		361
538	Immunotherapy for Alzheimer's disease: from anti- $\beta$ -amyloid to tau-based immunization strategies. <b>2012</b> , 4, 213-38		106
537	Treatment strategies targeting amyloid $\beta$ -protein. <b>2012</b> , 2, a006387		80
536	Alzheimer's therapeutics: translation of preclinical science to clinical drug development. <b>2012</b> , 37, 261-77		34
535	Detection and control of prion diseases in food animals. <b>2012</b> , 2012, 254739		8
534	Alzheimer's disease, cerebrovascular disease, and the $\beta$ -amyloid cascade. <b>2012</b> , 39, 712-28		128
533	Reducing available soluble $\beta$ -amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2012</b> , 71, 1009-17	3-1	8
532	Development of nucleic acid drugs for neurological disorders. <b>2012</b> , 12, 1621-9		2
531	39-week toxicity and toxicokinetic study of ponezumab (PF-04360365) in cynomolgus monkeys with 12-week recovery period. <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 28, 531-41	4-3	29
530	[Development of antibodies for immunotherapy of Alzheimer's disease]. <b>2012</b> , 52, 1168-70		1
529	Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: tangle formation, amyloid- $\beta$ and microglia in Alzheimer's disease. <b>2012</b> , 118, 331-7		29

528	Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2012</b> , 71, 362-81	3.1	1145
527	Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. <b>2012</b> , 8, 261-71		198
526	The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update. <b>2012</b> , 7, 281-97		33
525	Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease. <b>2012</b> , 53 Suppl 6, 45-52		80
524	Alzheimer's disease. <b>2012</b> , 65, 329-52		176
523	Systemic and central immunity in Alzheimer's disease: therapeutic implications. <b>2012</b> , 18, 64-76		25
522	Safety, tolerability, and antibody response of active A $\beta$ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. <b>2012</b> , 11, 597-604		217
521	Intracerebral immune complex formation induces inflammation in the brain that depends on Fc receptor interaction. <i>Acta Neuropathologica</i> , <b>2012</b> , 124, 479-90	14.3	33
520	Sustained levels of antibodies against A $\beta$ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice. <b>2012</b> , 238, 38-43		32
519	Identification and mapping of linear antigenic determinants of human amyloid (1-42) peptide. <b>2012</b> , 33, 26-34		1
518	Cerebral amyloid angiopathy. <b>2012</b> , 107, 41-78		47
517	Gantenerumab: a novel human anti-A $\beta$ antibody demonstrates sustained cerebral amyloid- $\beta$ binding and elicits cell-mediated removal of human amyloid- $\beta$ <i>Journal of Alzheimer's Disease</i> , <b>2012</b> , 28, 49-69	4.3	252
516	Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex. <b>2012</b> , 33, 2237-46		25
515	Amyloid- $\beta$ peptide: Dr. Jekyll or Mr. Hyde?. <i>Journal of Alzheimer's Disease</i> , <b>2013</b> , 33 Suppl 1, S111-20	4.3	78
514	Trans-cellular propagation of Tau aggregation by fibrillar species. <i>Journal of Biological Chemistry</i> , <b>2012</b> , 287, 19440-51	5.4	393
513	PET amyloid-beta imaging in preclinical Alzheimer's disease. <b>2012</b> , 1822, 370-9		102
512	Multiple Sclerosis, Alzheimer's Disease, and Inflammation: A Hypothetical View. <b>2012</b> , 215-252		
511	Intranasal inoculation with an adenovirus vaccine encoding ten repeats of A $\beta$ -10 reduces AD-like pathology and cognitive impairment in Tg-APP <sup>Swe</sup> /PSEN1 <sup>dE9</sup> mice. <b>2012</b> , 249, 16-26		12



510	Immunization with a new DNA vaccine for Alzheimer's disease elicited Th2 immune response in BALB/c mice by in vivo electroporation. <b>2012</b> , 313, 17-21	11
509	Protease-activated drug development. <b>2012</b> , 2, 156-78	187
508	Immunotherapy for Alzheimer disease: the challenge of adverse effects. <b>2012</b> , 8, 465-9	91
507	The therapeutic potential of the endocannabinoid system for Alzheimer's disease. <b>2012</b> , 16, 407-20	26
506	Immunotoxicity, Immune Dysfunction, and Chronic Disease. <b>2012</b> ,	4
505	Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. <b>2012</b> , 69, 198-207	288
504	Overview of Mouse Models for Psychiatric and Neurologic Disorders. <b>2012</b> , 738-751	
503	Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice. <b>2012</b> , 7, 37	30
502	Beta-amyloid peptides enhance the proliferative response of activated CD4CD28 lymphocytes from Alzheimer disease patients and from healthy elderly. <b>2012</b> , 7, e33276	22
501	Vaccine Development to Treat Alzheimer's Disease Neuropathology in APP/PS1 Transgenic Mice. <b>2012</b> , 2012, 376138	14
500	Microglia in Alzheimer's Disease: It's All About Context. <b>2012</b> , 2012, 314185	63
499	Targeting Beta amyloid: a clinical review of immunotherapeutic approaches in Alzheimer's disease. <b>2012</b> , 2012, 628070	55
498	A unifying hypothesis for familial and sporadic Alzheimer's disease. <b>2012</b> , 2012, 978742	6
497	Microglial Amyloid- $\beta$ -40 Phagocytosis Dysfunction Is Caused by High-Mobility Group Box Protein-1: Implications for the Pathological Progression of Alzheimer's Disease. <b>2012</b> , 2012, 685739	32
496	Alzheimer's disease and related dementias. 17-31	
495	Alzheimer's disease. 149-167	
494	Predicting cerebral amyloid angiopathy-related intracerebral hemorrhages and other cerebrovascular disorders in Alzheimer's disease. <b>2012</b> , 3, 64	23
493	Reversal of paralysis and reduced inflammation from peripheral administration of $\beta$ amyloid in TH1 and TH17 versions of experimental autoimmune encephalomyelitis. <b>2012</b> , 4, 145ra105	73

492	βAmyloid: enemy or remedy?. <b>2012</b> , 4, 145fs24	3
491	New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. <b>2012</b> , 73, 504-17	207
490	'Clinical trials in Alzheimer's disease': immunotherapy approaches. <b>2012</b> , 120 Suppl 1, 186-193	105
489	Stromal cell-derived factor 1 decreases βAmyloid deposition in Alzheimer's disease mouse model. <b>2012</b> , 1459, 15-26	25
488	Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease. <b>2012</b> , 244, 70-83	12
487	Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. <b>2012</b> , 134, 8-25	153
486	Recent rodent models for Alzheimer's disease: clinical implications and basic research. <b>2012</b> , 119, 173-95	85
485	Microglia and neurodegeneration: the role of systemic inflammation. <b>2013</b> , 61, 71-90	496
484	Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. <b>2013</b> , 6, 423-42	7
483	Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine. <b>2013</b> , 11, 81	30
482	Nonhuman amyloid oligomer epitope reduces Alzheimer's-like neuropathology in 3xTg-AD transgenic mice. <b>2013</b> , 48, 931-40	9
481	Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET. <b>2013</b> , 40, 908-20	28
480	Antibodies bound to Aβ oligomers potentiate the neurotoxicity of Aβ by activating microglia. <b>2013</b> , 126, 604-15	15
479	Soluble amyloid precursor protein 770 is a novel biomarker candidate for acute coronary syndrome. <b>2013</b> , 7, 657-63	2
478	The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 479-97	14.3 287
477	CD4 T cells in immunity and immunotherapy of Alzheimer's disease. <b>2013</b> , 139, 438-46	42
476	What does complement do in Alzheimer's disease? Old molecules with new insights. <b>2013</b> , 2, 21	39
475	Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer's disease. <b>2013</b> , 1, 48	31

474	Immunization targeting a minor plaque constituent clears $\beta$ amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. <b>2013</b> , 34, 137-45	32
473	Noninfectious disease vaccines. <b>2013</b> , 1138-1145	
472	Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. <b>2013</b> , 34, 2613-22	26
471	Pathogenesis of herpes stromal keratitis--a focus on corneal neovascularization. <b>2013</b> , 33, 1-9	73
470	Transgenic expression of $\beta$ antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice. <b>2013</b> , 34, 2866-78	4
469	An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. <b>2013</b> , 34, 1550-5	24
468	Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. <b>2013</b> , 33, 4923-34	81
467	Immune effects of optimized DNA vaccine and protective effects in a MPTP model of Parkinson's disease. <b>2013</b> , 34, 1559-70	13
466	Review: activation patterns of microglia and their identification in the human brain. <b>2013</b> , 39, 3-18	613
465	Use of animal models of human disease for nonclinical safety assessment of novel pharmaceuticals. <b>2013</b> , 41, 508-18	61
464	Extracellular chaperones and proteostasis. <b>2013</b> , 82, 295-322	110
463	Inhibitor Design Against Cytotoxic $\beta$ Amyloid Species. <b>2013</b> , 187-206	
462	Inhibitors of Amyloid and Oligomer Formation. <b>2013</b> , 345-372	1
461	MER5101, a novel A $\beta$ -15:DT conjugate vaccine, generates a robust anti-A $\beta$ antibody response and attenuates A $\beta$ pathology and cognitive deficits in APPswe/PS1E9 transgenic mice. <b>2013</b> , 33, 7027-37	43
460	Immunotherapy against amyloid pathology in Alzheimer's disease. <b>2013</b> , 333, 50-4	36
459	Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?. <b>2013</b> , 13, 1075-84	83
458	Differential X-ray phase contrast tomography of Alzheimer plaques in mouse models: perspectives for drug development and clinical imaging techniques. <b>2013</b> , 8, C05005-C05005	
457	Cerebral microbleeds: a guide to detection and clinical relevance in different disease settings. <b>2013</b> , 55, 655-74	59

456	Microglia actions in Alzheimer's disease. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 461-77	14.3	209
455	APOE- $\epsilon$ and APOE- $\epsilon$ correlate with increased amyloid accumulation in cerebral vasculature. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2013</b> , 72, 708-15	3.1	60
454	Immunological aspects and anti-amyloid strategy for Alzheimer's dementia. <b>2013</b> , 64, 603-8		2
453	Inflammatory components in human Alzheimer's disease and after active amyloid- $\beta$ immunization. <b>2013</b> , 136, 2677-96		165
452	Brain hemorrhages in cerebral amyloid angiopathy. <b>2013</b> , 39, 955-62		11
451	Immunocytochemical characterization of Alzheimer disease hallmarks in APP/PS1 transgenic mice treated with a new anti-amyloid- $\beta$ vaccine. <b>2013</b> , 2013, 709145		13
450	A tetra(ethylene glycol) derivative of benzothiazole aniline enhances Ras-mediated spinogenesis. <b>2013</b> , 33, 9306-18		22
449	The neuroprotective effect of immune serum of adeno-associated virus vaccine containing A $\beta$ -15 gene on amyloid toxicity. <b>2013</b> , 16, 603-8		
448	Early intervention in the 3xTg-AD mice with an amyloid $\beta$ antibody fragment ameliorates first hallmarks of Alzheimer disease. <b>2013</b> , 5, 665-77		41
447	Neurotoxic amyloid beta oligomeric assemblies recreated in microfluidic platform with interstitial level of slow flow. <b>2013</b> , 3, 1921		61
446	Amyloid- $\beta$ increases capillary bed density in the adult zebrafish retina. <b>2013</b> , 54, 1516-21		17
445	Disease modifying therapies for Alzheimer's disease targeting A $\beta$ oligomers: implications for therapeutic mechanisms. <b>2013</b> , 2013, 984041		8
444	Epitope structure and binding affinity of single chain llama anti- $\beta$ amyloid antibodies revealed by proteolytic excision affinity-mass spectrometry. <b>2013</b> , 26, 1-9		13
443	Plasmid DNA-based gene therapy in neurological disorders. <b>2013</b> , 46-56		
442	The Role of MicroRNAs in Alzheimer's Disease. <b>2013</b> , 539-552		1
441	Central amyloid- $\beta$ specific single chain variable fragment ameliorates A $\beta$ aggregation and neurotoxicity. <b>2013</b> , 26, 571-80		13
440	Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. <b>2013</b> , 9, 1002-10		26
439	Angiotensin-receptor blockers, hypertension and Alzheimer disease--the entangled relationship. <b>2013</b> , 77, 315-6		7

438	[Molecular targeting and translational research for new therapeutic strategies on Alzheimer's disease]. <b>2013</b> , 133, 1389-99	1
437	Cessation of neoangiogenesis in Alzheimer's disease follows amyloid-beta immunization. <b>2013</b> , 3, 1354	25
436	Immune activation in amyloid- $\beta$ -related angiitis correlates with decreased parenchymal amyloid- $\beta$ plaque load. <b>2014</b> , 13, 38-44	13
435	What can we learn from regional vulnerability to amyloid- $\beta$ -accumulation in nondemented individuals?. <b>2013</b> , 3, 187-189	2
434	Inhibition of neointima formation through DNA vaccination for apolipoprotein(a): a new therapeutic strategy for lipoprotein(a). <b>2013</b> , 3, 1600	5
433	Molecular Mechanism Underlying A $\beta$ Immunotherapy: Implications for the Toxic Action of A $\beta$ Oligomers. <b>2013</b> , 02,	1
432	Hereditary and sporadic beta-amyloidoses. <b>2013</b> , 18, 1202-26	6
431	Bapineuzumab alters a $\beta$ -composition: implications for the amyloid cascade hypothesis and anti-amyloid immunotherapy. <b>2013</b> , 8, e59735	26
430	Therapeutic vaccines against human and rat renin in spontaneously hypertensive rats. <b>2013</b> , 8, e66420	13
429	Curcumin: a natural substance with potential efficacy in Alzheimer's disease. <b>2013</b> , 5, 23-31	31
428	Emerging Therapeutic Strategies in Alzheimer's Disease. <b>2013</b> ,	1
427	Potential Therapeutic Strategies to Prevent the Progression of Alzheimer to Disease States. <b>2013</b> ,	2
426	Oral administration of a fusion protein between the cholera toxin B subunit and the 42-amino acid isoform of amyloid- $\beta$ -peptide produced in silkworm pupae protects against Alzheimer's disease in mice. <b>2014</b> , 9, e113585	8
425	Pathogenesis of Alzheimer disease: role of oxidative stress, amyloid- $\beta$ -peptides, systemic ammonia and erythrocyte energy metabolism. <b>2014</b> , 13, 112-9	36
424	Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. <b>2014</b> , 5, 47	20
423	Peptide Vaccines for Hypertension and Diabetes Mellitus. <b>2014</b> , 2, 832-40	4
422	Therapeutic vaccines for hypertension and dyslipidemia. <b>2014</b> , 55, 96-100	14
421	Alzheimer's disease. 391-410	1

420 Biomarkers of Alzheimer's disease. **2014**, 801-815

419 Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance. **2014**, 192, 92-102 34

418 Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. **2014**, 14, 973-86 33

417 Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease. **2014**, 2, 135 175

416 Women with the Alzheimer's risk marker ApoE4 lose A $\beta$ -specific CD4+ T cells 10-20 years before men. **2014**, 4, e414 6

415 Potential therapeutic strategies for Alzheimer's disease targeting or beyond  $\beta$ -amyloid: insights from clinical trials. **2014**, 2014, 837157 45

414 Zerebrale Mikroblutungen: Leitfaden f $\ddot{u}$ r den Nachweis und die klinische Relevanz bei verschiedenen Krankheitsbildern. **2014**, 04, 123-147

413 Failure of perivascular drainage of  $\beta$ -amyloid in cerebral amyloid angiopathy. **2014**, 24, 396-403 99

412 Degradation of amyloid beta by human induced pluripotent stem cell-derived macrophages expressing neprilysin-2. **2014**, 13, 442-53 38

411 Amyloid beta peptide immunotherapy in Alzheimer disease. **2014**, 170, 739-48 21

410 A dual vaccine against influenza & Alzheimer's disease failed to enhance anti- $\beta$ -amyloid antibody responses in mice with pre-existing virus specific memory. **2014**, 277, 77-84 4

409 Amyloid- $\beta$ -directed immunotherapy for Alzheimer's disease. **2014**, 275, 284-95 106

408 A $\beta$ -immunotherapy for Alzheimer's disease: effects on apoE and cerebral vasculopathy. *Acta Neuropathologica*, **2014**, 128, 777-89 143 32

407 Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders. **2014**, 3, 25 48

406 Vaccination against Alzheimer disease: an update on future strategies. **2014**, 10, 847-51 25

405 Dementia. **2014**, 70-92

404 Complex regulation of acute and chronic neuroinflammatory responses in mouse models deficient for nuclear factor kappa B p50 subunit. **2014**, 64, 16-29 19

403 Loss of P2Y $_1$ -nucleotide receptors enhances early pathology in the TgCRND8 mouse model of Alzheimer's disease. **2014**, 49, 1031-42 44

402	Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. <b>2014</b> , 268, 50-7	6
401	Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis. <b>2014</b> , 88, 486-94	46
400	Immunotherapy for Alzheimer's disease. <b>2014</b> , 88, 499-507	77
399	Afferent and efferent immunological pathways of the brain. Anatomy, function and failure. <b>2014</b> , 36, 9-14	66
398	Therapeutic vaccine against DPP4 improves glucose metabolism in mice. <b>2014</b> , 111, E1256-63	31
397	Active immunotherapy options for Alzheimer's disease. <b>2014</b> , 6, 7	58
396	Amyloid beta-related angiitis--a case report and comprehensive review of literature of 94 cases. <b>2014</b> , 44, 86-92	50
395	Calcium channelopathies and Alzheimer's disease: insight into therapeutic success and failures. <b>2014</b> , 739, 83-95	60
394	The role of amyloid-beta in the regulation of memory. <b>2014</b> , 88, 479-85	72
393	Emerging therapeutics for Alzheimer's disease. <b>2014</b> , 54, 381-405	63
392	Cerebral microbleeds: overview and implications in cognitive impairment. <b>2014</b> , 6, 33	103
391	Vascular and parenchymal amyloid pathology in an Alzheimer disease knock-in mouse model: interplay with cerebral blood flow. <b>2014</b> , 9, 28	57
390	Perspectives on future Alzheimer therapies: amyloid- $\beta$ protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease. <b>2014</b> , 6, 16	96
389	Crystal structure reveals conservation of amyloid- $\beta$ conformation recognized by 3D6 following humanization to bapineuzumab. <b>2014</b> , 6, 31	26
388	A brief overview of amyloids and Alzheimer's disease. <b>2014</b> , 23, 1315-31	74
387	The amyloid hypothesis, time to move on: Amyloid is the downstream result, not cause, of Alzheimer's disease. <b>2014</b> , 10, 372-80	157
386	Cerebral microbleeds in a multiethnic elderly community: demographic and clinical correlates. <b>2014</b> , 345, 125-30	25
385	Vaccine efficacy of transcutaneous immunization with amyloid $\beta$ using a dissolving microneedle array in a mouse model of Alzheimer's disease. <b>2014</b> , 266, 1-11	42

384	DNA Vaccines. <b>2014</b> ,		2
383	A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. <b>2014</b> , 76, 185-205		188
382	p-Tau immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. <b>2014</b> , 575, 96-100		39
381	[A case report of cerebral amyloid angiopathy-related inflammation treated with cyclophosphamide]. <b>2014</b> , 54, 46-51		1
380	Apolipoprotein C-III is an amyloid- $\beta$ -binding protein and an early marker for Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 855-65	4-3	43
379	Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 39, 423-40	4-3	17
378	Alzheimer's disease: is a vaccine possible?. <b>2014</b> , 47, 438-44		10
377	Harnessing the immune system for treatment and detection of tau pathology. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 40 Suppl 1, S113-21	4-3	17
376	Treatment of Dementia. <b>2014</b> , 556-585		
375	Cognitive Enhancers and Treatments for Alzheimer's Disease. <b>2015</b> , 2236-2260		
374	Beta-Amyloid-orientierte Therapien der Alzheimer-Krankheit. <b>2015</b> , 16, 50-59		
373	Vaccine-induced A $\beta$ -specific CD8 <sup>+</sup> T cells do not trigger autoimmune neuroinflammation in a murine model of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , <b>2015</b> , 12, 95	10-1	8
372	Perspectives on Inhibiting $\beta$ -Amyloid Aggregation through Structure-Based Drug Design. <b>2015</b> , 10, 1467-74		21
371	Cerebral amyloid angiopathy: emerging concepts. <b>2015</b> , 17, 17-30		192
370	Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases. <b>2015</b> , 4, 170-196		3
369	Single chain variable fragment against a $\beta$ -expressed in baculovirus inhibits a $\beta$ -fibril elongation and promotes its disaggregation. <b>2015</b> , 10, e0124736		5
368	The Peptide Vaccine Combined with Prior Immunization of a Conventional Diphtheria-Tetanus Toxoid Vaccine Induced Amyloid $\beta$ -Binding Antibodies on Cynomolgus Monkeys and Guinea Pigs. <b>2015</b> , 2015, 786501		4
367	A comparative evaluation of a novel vaccine in APP/PS1 mouse models of Alzheimer's disease. <b>2015</b> , 2015, 807146		12



366	Alzheimer's disease and immunotherapy: what is wrong with clinical trials?. <b>2015</b> , 4, 27-34	13
365	Post-mortem analysis of neuroinflammatory changes in human Alzheimer's disease. <b>2015</b> , 7, 42	56
364	A generic class of amyloid fibril inhibitors. <b>2015</b> , 3, 1350-1359	10
363	IL10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. <b>2015</b> , 85, 534-48	236
362	Targeting microglia for the treatment of Alzheimer's disease. <b>2015</b> , 19, 497-506	58
361	Effect of amyloid- $\beta$ immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3 $\beta$ <b>2015</b> , 41, 445-57	17
360	Development of DNA vaccines as an anti-hypertensive therapy or for anti-angiogenesis. <b>2015</b> , 15, 431-6	2
359	New progress in active immunotherapy targeting to amyloid beta. <b>2015</b> , 58, 383-389	1
358	A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease. <b>2015</b> , 11, 1246-59	46
357	Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes. <b>2015</b> , 36, 2702-8	73
356	Reducing A $\beta$ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease. <b>2015</b> , 764, 571-581	38
355	Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials. <b>2015</b> , 29, 487-502	22
354	The Inflammatory Form of Cerebral Amyloid Angiopathy or "Cerebral Amyloid Angiopathy-Related Inflammation" (CAARI). <b>2015</b> , 15, 54	38
353	A selective prostaglandin E2 receptor subtype 2 (EP2) antagonist increases the macrophage-mediated clearance of amyloid-beta plaques. <b>2015</b> , 58, 5256-73	31
352	Alzheimer's disease clinical trials: past failures and future opportunities. <b>2015</b> , 5, 297-309	11
351	Immunotherapeutic approaches for Alzheimer's disease. <b>2015</b> , 85, 1162-76	197
350	Forme inflammatoire d'angiopathie c�r�brale du sujet �g�. <b>2015</b> , 15, 116-121	
349	Alzheimer's Disease and Mechanism-Based Attempts to Enhance Cognition. <b>2015</b> , 193-231	

348	Impact of amyloid $\beta$ aggregate maturation on antibody treatment in APP23 mice. <b>2015</b> , 3, 41	7
347	An anti-pyroglutamate-3 A $\beta$ vaccine reduces plaques and improves cognition in APPswe/PS1E9 mice. <b>2015</b> , 36, 3187-3199	36
346	Adverse effects of a SOD1-peptide immunotherapy on SOD1 G93A mouse slow model of amyotrophic lateral sclerosis. <b>2015</b> , 310, 38-50	6
345	Matrix metalloproteinase 9-mediated intracerebral hemorrhage induced by cerebral amyloid angiopathy. <b>2015</b> , 36, 2963-2971	27
344	Targeting protein aggregation for the treatment of degenerative diseases. <b>2015</b> , 14, 759-80	255
343	Transport of cargo from periphery to brain by circulating monocytes. <b>2015</b> , 1622, 328-38	12
342	Methods to monitor monocytes-mediated amyloid-beta uptake and phagocytosis in the context of adjuvanted immunotherapies. <b>2015</b> , 424, 64-79	11
341	Aging Mechanisms. <b>2015</b> ,	3
340	Cerebral amyloid angiopathy, subcortical white matter disease and dementia: literature review and study in OPTIMA. <b>2015</b> , 25, 51-62	37
339	White matter changes in dementia: role of impaired drainage of interstitial fluid. <b>2015</b> , 25, 63-78	105
338	Tau aggregation and its interplay with amyloid- $\beta$ <i>Acta Neuropathologica</i> , <b>2015</b> , 129, 207-20	14.3 222
337	Combined treatment of amyloid- $\beta$ and CD40-stimulated bone marrow-derived dendritic cells plus splenocytes from young mice prevents the development of Alzheimer's disease in APPswe/PSEN1E9 mice. <b>2015</b> , 36, 111-22	12
336	Effect of active A $\beta$ immunotherapy on neurons in human Alzheimer's disease. <b>2015</b> , 235, 721-30	28
335	P2Y receptors in Alzheimer's disease. <b>2015</b> , 107, 1-21	27
334	Emerging concepts in Alzheimer's disease. <b>2015</b> , 10, 291-319	152
333	A review on Alzheimer's disease pathophysiology and its management: an update. <b>2015</b> , 67, 195-203	871
332	Editorial: From Current Diagnostic Tools and Therapeutics for Alzheimer's Disease Towards Earlier Diagnostic Markers and Treatment Targets. <b>2017</b> , 14, 2-5	13
331	A Simulation Model of Periarterial Clearance of Amyloid- $\beta$ from the Brain. <b>2016</b> , 8, 18	25

330	Amyloidosis in Retinal Neurodegenerative Diseases. <b>2016</b> , 7, 127		23
329	The amyloid cascade hypothesis: are we poised for success or failure?. <b>2016</b> , 139 Suppl 2, 237-252		235
328	Targeting microglia for the treatment of Alzheimer's Disease. <b>2016</b> , 64, 1710-32		113
327	Virus-based nanoparticles as platform technologies for modern vaccines. <b>2016</b> , 8, 554-78		46
326	ABCA7 Mediates Phagocytic Clearance of Amyloid- $\beta$ in the Brain. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 569-84	4-3	50
325	An Oral A $\beta$ Vaccine Using a Recombinant Adeno-Associated Virus Vector in Aged Monkeys: Reduction in Plaque Amyloid and Increase in A $\beta$ Oligomers. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 54, 1047-1059	4-3	17
324	Familial Presenilin Mutations and Sporadic Alzheimer's Disease Pathology: Is the Assumption of Biochemical Equivalence Justified?. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 50, 645-58	4-3	9
323	Inflammation, Aging, and Oxidative Stress. <b>2016</b> ,		8
322	Two Phase 2 Multiple Ascending-Dose Studies of Vanutide Cridifcar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 51, 1131-43	4-3	53
321	Piceatannol, a natural analogue of resveratrol, effectively reduces beta-amyloid levels via activation of alpha-secretase and matrix metalloproteinase-9. <b>2016</b> , 23, 124-134		14
320	Longitudinal noninvasive magnetic resonance imaging of brain microhemorrhages in BACE inhibitor-treated APP transgenic mice. <b>2016</b> , 45, 50-60		11
319	Expression in plants of two new antigens with implications in Alzheimer's disease immunotherapy. <b>2016</b> , 126, 361-370		5
318	Antibody-Based Drugs and Approaches Against Amyloid- $\beta$ Species for Alzheimer's Disease Immunotherapy. <b>2016</b> , 33, 685-697		39
317	Animal Models of Behavior Genetics. <b>2016</b> ,		
316	Neurodegenerative Diseases and Dementia. <b>2016</b> , 167-197		
315	Interactions between inflammation, sex steroids, and Alzheimer's disease risk factors. <b>2016</b> , 43, 60-82		57
314	The endocytic pathway in microglia during health, aging and Alzheimer's disease. <b>2016</b> , 32, 89-103		56
313	Pathophysiology of Lymphatic Drainage of the Central Nervous System. <b>2016</b> , 479-501		1

312 Fokus auf Amyloid und Tau. **2016**, 18, 46-55

311 Prospects and Challenges for Alzheimer Therapeutics. **2016**, 605-637

0

310 Immunotherapy Against Amyloid- $\beta$  In Alzheimer's Disease: An Overview. **2016**, 3-17

1

309 Active Immunization Against the Amyloid- $\beta$  Peptide. **2016**, 19-35

308 A $\beta$ -Degrading Proteases: Therapeutic Potential in Alzheimer Disease. **2016**, 30, 667-75

17

307 Neuronal histamine and cognitive symptoms in Alzheimer's disease. **2016**, 106, 135-45

53

306 Pharmacological properties of a novel and potent B-secretase modulator as a therapeutic option for the treatment of Alzheimer's disease. **2016**, 1633, 73-86

13

305 Positive modulators of the  $\alpha 7$  nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease. **2016**, 144, 142-57

61

304 Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. **2016**, 46, 57-87

11

303 Single administration of a novel B-secretase modulator ameliorates cognitive dysfunction in aged C57BL/6J mice. **2016**, 1633, 52-61

1

302 Pseudotumoral presentation of cerebral amyloid angiopathy-related inflammation. **2016**, 86, 912-9

26

301 Regulatory T cells delay disease progression in Alzheimer-like pathology. **2016**, 139, 1237-51

162

300 "No screams and cries will convince us that white is white and black is black" an ode to the defenders of amyloid cascade hypothesis of Alzheimer's disease. **2016**, 327-328, 35-42

6

299 Cerebral Innate Immunity. **2016**, 361-386

298 ACAID as a potential therapeutic approach to modulate inflammation in neurodegenerative diseases. **2016**, 88, 38-45

7

297 Immunotherapies in Alzheimer's disease: Too much, too little, too late or off-target?. *Acta Neuropathologica*, **2016**, 131, 481-504

14.3 25

296 Developing therapeutic vaccines against Alzheimer's disease. **2016**, 15, 401-15

46

295 Discovery of a Small Molecule that Enhances Astrocytogenesis by Activation of STAT3, SMAD1/5/8, and ERK1/2 via Induction of Cytokines in Neural Stem Cells. *ACS Chemical Neuroscience*, **2016**, 7, 90-9

5.7 12

294	Why therapies for Alzheimer's disease do not work: Do we have consensus over the path to follow?. <b>2016</b> , 25, 70-84	19
293	Gene Therapy for Neurological Disorders. <b>2016</b> ,	
292	Future Treatments of Memory Loss, Alzheimer's Disease, and Dementia. <b>2016</b> , 187-199	1
291	Antibody Therapeutics Targeting A $\beta$ and Tau. <b>2017</b> , 7,	30
290	Application to Gene Therapy and Vaccination. <b>2017</b> , 885-906	
289	Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of $\beta$ Amyloid in an Animal Model of Alzheimer's Disease. <b>2017</b> , 25, 153-164	10
288	Targets and Mechanisms in Prevention of Parkinson's Disease through Immunomodulatory Treatments. <b>2017</b> , 85, 321-330	14
287	Immune Regulation of Antibody Access to Neuronal Tissues. <b>2017</b> , 23, 227-245	33
286	AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy. <b>2017</b> , 214, 1227-1238	36
285	Peritoneal dialysis reduces amyloid-beta plasma levels in humans and attenuates Alzheimer-associated phenotypes in an APP/PS1 mouse model. <i>Acta Neuropathologica</i> , <b>2017</b> , 134, 207-220 <sup>14,3</sup>	56
284	Dysregulated Metabolism of the Amyloid- $\beta$ Protein and Therapeutic Approaches in Alzheimer Disease. <b>2017</b> , 118, 4183-4190	20
283	A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment. <b>2017</b> , 77, 92-105	10
282	Alzheimer Disease: Scientific Breakthroughs and Translational Challenges. <b>2017</b> , 92, 978-994	45
281	Therapeutic Strategies in Neurodegenerative Diseases. <b>2017</b> , 681-711	
280	Young microglia restore amyloid plaque clearance of aged microglia. <b>2017</b> , 36, 583-603	75
279	Safety and Efficacy of Anti-Amyloid- $\beta$ Immunotherapy in Alzheimer's Disease: A Systematic Review and Meta-Analysis. <b>2017</b> , 12, 194-203	43
278	Immunotherapy for Alzheimer's Disease. <b>2017</b> , 753-766	
277	Non human primate models for Alzheimer's disease-related research and drug discovery. <b>2017</b> , 12, 187-200	34

276	Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease. <b>2017</b> , 77, 47-65	144
275	Construction of a lentiviral vector containing shRNA targeting ADAM17 and its role in attenuating endotoxemia in mice. <b>2017</b> , 16, 6013-6019	2
274	Lessons from Anti-Amyloid- $\beta$ Immunotherapies in Alzheimer Disease: Aiming at a Moving Target. <b>2017</b> , 17, 242-250	26
273	Applications for Treatment of Neurodegenerative Diseases. <b>2017</b> , 99-134	4
272	Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease. <b>2017</b> , 43, 553-570	35
271	APP/A $\beta$ structural diversity and Alzheimer's disease pathogenesis. <b>2017</b> , 110, 1-13	59
270	The companion dog as a unique translational model for aging. <b>2017</b> , 70, 141-153	27
269	An A $\beta$ -10-KLH vaccine reduced Alzheimer's disease-like pathology and had a sustained effect in Tg-APPswe/PSEN1dE9 mice. <b>2017</b> , 1673, 72-77	8
268	Evaluation of a DNA A $\beta$ 2 Vaccine in Aged NZW Rabbits: Antibody Kinetics and Immune Profile after Intradermal Immunization with Full-Length DNA A $\beta$ 2 Trimer. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 57, 97-112	4-3 10
267	Evaluation of a DNA A $\beta$ 2 vaccine in adult rhesus monkeys ( <i>Macaca mulatta</i> ): antibody kinetics and immune profile after intradermal immunization with full-length DNA A $\beta$ 2 trimer. <b>2017</b> , 9, 30	13
266	A novel antibody targeting sequence 31-35 in amyloid $\beta$ protein attenuates Alzheimer's disease-related neuronal damage. <b>2017</b> , 27, 122-133	5
265	Molecular Imaging and Precision Medicine in Dementia and Movement Disorders. <b>2017</b> , 12, 119-136	1
264	A $\beta$ vaccination in combination with behavioral enrichment in aged beagles: effects on cognition, A $\beta$ and microhemorrhages. <b>2017</b> , 49, 86-99	15
263	The Threshold Theory for Parkinson's Disease. <b>2017</b> , 40, 4-14	111
262	Animal models of dementia. 77-93	
261	Overview and Current Status of Alzheimer's Disease in Bangladesh. <b>2017</b> , 1, 27-42	5
260	Perspective, Summary, and Directions for Future Research on Alzheimer's Disease. <b>2017</b> , 361-386	
259	Membrane-Accelerated Amyloid- $\beta$ Aggregation and Formation of Cross- $\beta$ Sheets. <b>2017</b> , 7,	22

258	Ultra-Early Phase pathologies of Alzheimer's disease and other neurodegenerative diseases. <b>2017</b> , 93, 361-377		6
257	Vaccination to Treat Noninfectious Diseases. <b>2017</b> , 421-444		
256	Amyloid: Vascular and Parenchymal ?. <b>2017</b> ,		2
255	Production of an anti-A $\beta$ antibody fragment in <i>Pichia pastoris</i> and in vitro and in vivo validation of its therapeutic effect. <b>2017</b> , 12, e0181480		16
254	Efficacy and Safety of the Immunization with DNA for Alzheimer's Disease in Animal Models: A Systematic Review from Literature. <b>2017</b> , 1, 195-217		6
253	Current status of vaccines in psychiatry-A narrative review. <b>2018</b> , 31, 112-120		5
252	Convergent molecular defects underpin diverse neurodegenerative diseases. <b>2018</b> , 89, 962-969		15
251	Dale Schenk One Year Anniversary: Fighting to Preserve the Memories. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1-13	4.3	4
250	Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques. <b>2018</b> , 303, 48-58		6
249	In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain. <b>2018</b> , 273, 108-130		35
248	Neuroinflammatory responses in Alzheimer's disease. <b>2018</b> , 125, 771-779		71
247	Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode. <b>2018</b> , 22, 149-162		37
246	Alzheimer's Disease, Oligomers, and Inflammation. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1261-1276	4.3	89
245	Granulocyte-macrophage colony-stimulating factor neuroprotective activities in Alzheimer's disease mice. <b>2018</b> , 319, 80-92		30
244	The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study. <b>2018</b> , 28, 1215-1226		6
243	Downregulated apoptosis and autophagy after anti-A $\beta$ immunotherapy in Alzheimer's disease. <b>2018</b> , 28, 603-610		12
242	Present and Future Therapies for Alzheimer's Disease. <b>2018</b> ,		
241	Epitomic Characterization of the Specificity of the Anti-Amyloid A $\beta$ Monoclonal Antibodies 6E10 and 4G8. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 66, 1235-1244	4.3	21

240	Structural Optimization of Foldamer-Dendrimer Conjugates as Multivalent Agents against the Toxic Effects of Amyloid Beta Oligomers. <b>2018</b> , 23,	7
239	Early minor stimulation of microglial TLR2 and TLR4 receptors attenuates Alzheimer's disease-related cognitive deficit in rats: behavioral, molecular, and electrophysiological evidence. <b>2018</b> , 70, 203-216	36
238	Subspace Network. <b>2018</b> ,	3
237	Drug Management of the Dementias. <b>2018</b> , 623-627	
236	The Physiological Roles of Amyloid- $\beta$ Peptide Hint at New Ways to Treat Alzheimer's Disease. <b>2018</b> , 10, 118	140
235	Antibody Engineering for Optimized Immunotherapy in Alzheimer's Disease. <b>2018</b> , 12, 254	11
234	Safety, tolerability and immunogenicity of an active anti-A $\beta$ vaccine (ABvac40) in patients with Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase I trial. <b>2018</b> , 10, 12	33
233	An autopsy case of amyloid $\beta$ -related angiitis with cognitive impairment, multiple infarcts and subcortical hemorrhage. <b>2018</b> , 14, 47-51	
232	Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. <b>2018</b> , 117, 62-71	12
231	Prophylactic and Therapeutic Applications of Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer's Disease. <b>2018</b> , 139-161	1
230	Noninfectious Disease Vaccines. <b>2018</b> , 689-697.e4	1
229	Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases. <b>2019</b> , 33, 883-904	14
228	The role of Locus Coeruleus in neuroinflammation occurring in Alzheimer's disease. <b>2019</b> , 153, 47-58	16
227	Antibody-based therapies for Huntington's disease: current status and future directions. <b>2019</b> , 132, 104569	9
226	Recent Trends in Microneedle Development & Applications in Medicine and Cosmetics (2013-2018). <b>2019</b> , 95-144	2
225	Anti-A $\beta$ Antibodies and Cerebral Amyloid Angiopathy Complications. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 1534	8.4 13
224	Microneedles for Transdermal Drug Delivery. <b>2019</b> ,	5
223	Rapid Cognitive Decline and Recurrent Falls in a 71 Year-Old Man Due to Cerebral Amyloidangiopathy-Related Inflammation (CAA-RI). <b>2019</b> , 4,	3



222	. <b>2019</b> ,		0
221	Targeting tauopathy with engineered tau-degrading intrabodies. <b>2019</b> , 14, 38		14
220	Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 71, 715-732	4.3	58
219	Homomeric and Heteromeric A $\beta$ Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype. <i>Frontiers in Molecular Neuroscience</i> , <b>2019</b> , 12, 176	6.1	4
218	A $\beta$ 3 in human Alzheimer's disease: effects of active A $\beta$ 2 immunization. <b>2019</b> , 7, 141		13
217	Protective and Regenerative Roles of T Cells in Central Nervous System Disorders. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2171	8.4	15
216	Royal Jelly Alleviates Cognitive Deficits and $\beta$ Amyloid Accumulation in APP/PS1 Mouse Model Via Activation of the cAMP/PKA/CREB/BDNF Pathway and Inhibition of Neuronal Apoptosis. <b>2018</b> , 10, 428		28
215	The Promises and Challenges of Erythropoietin for Treatment of Alzheimer's Disease. <b>2019</b> , 21, 12-24		22
214	A short perspective on the long road to effective treatments for Alzheimer's disease. <b>2019</b> , 176, 3636-3648		9
213	[Drug treatment of Alzheimer's dementia : Status quo and perspectives]. <b>2019</b> , 60, 761-768		6
212	Persistent neuropathological effects 14 years following amyloid- $\beta$ immunization in Alzheimer's disease. <b>2019</b> , 142, 2113-2126		74
211	Production of the herb <i>Ruta chalepensis</i> L. expressing amyloid $\beta$ GFP fusion protein. <b>2019</b> , 95, 295-302		1
210	Novel Therapeutic Potentials of Taxifolin for Amyloid- $\beta$ Associated Neurodegenerative Diseases and Other Diseases: Recent Advances and Future Perspectives. <b>2019</b> , 20,		15
209	Clinical trials of prion disease therapeutics. <b>2019</b> , 44, 53-60		9
208	Development of a Multicomponent Intervention to Prevent Alzheimer's Disease. <b>2019</b> , 10, 490		16
207	Current and Prospective Treatments for Alzheimer's Disease (and Other Neurodegenerative Diseases). <b>2019</b> , 391-442		1
206	Dementias. <b>2019</b> , 287-345		1
205	Curcumin Offers Potential Efficacy for Treating Alzheimer's Disease. <b>2019</b> , 191-209		2

204	Effects of a 15-amino-acid isoform of amyloid- $\beta$ expressed by silkworm pupae on B6C3-Tg Alzheimer's disease transgenic mice. <b>2019</b> , 296, 83-92		1
203	Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer's disease. <i>Journal of Neuroinflammation</i> , <b>2019</b> , 16, 74	10.1	73
202	Impact of Gold Nanoparticles on Amyloid $\beta$ -Induced Alzheimer's Disease in a Rat Animal Model: Involvement of STIM Proteins. <i>ACS Chemical Neuroscience</i> , <b>2019</b> , 10, 2299-2309	5.7	41
201	Effects of Microglial Cytokines on Alzheimer's Disease-Related Phenomena. <i>Journal of Alzheimer's Disease</i> , <b>2019</b> , 67, 1021-1034	4.3	1
200	Biomarkers of Alzheimer's Disease. <b>2019</b> , 885-894		
199	Recombinant influenza A viruses as vaccine vectors. <b>2019</b> , 18, 379-392		4
198	Neuroimmune interactions in Alzheimer's disease-New frontier with old challenges?. <b>2019</b> , 168, 183-201		4
197	IL-1 $\beta$ -driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia. <i>Journal of Neuroinflammation</i> , <b>2019</b> , 16, 261	10.1	17
196	Alzheimer's Disease and Dementia. <b>2019</b> , 25-82		0
195	Extracellular tau induces microglial phagocytosis of living neurons in cell cultures. <b>2020</b> , 154, 316-329		11
194	From Stroke to Dementia: a Comprehensive Review Exposing Tight Interactions Between Stroke and Amyloid- $\beta$ Formation. <b>2020</b> , 11, 601-614		44
193	The effect of insomnia on development of Alzheimer's disease. <i>Journal of Neuroinflammation</i> , <b>2020</b> , 17, 289	10.1	13
192	Analyzing microglial-associated A $\beta$ in Alzheimer's disease transgenic mice with a novel mid-domain A $\beta$ antibody. <b>2020</b> , 10, 10590		1
191	Novel antibodies detect additional $\beta$ -synuclein pathology in synucleinopathies: potential development for immunotherapy. <b>2020</b> , 12, 159		11
190	Antibody Fragments as Tools for Elucidating Structure-Toxicity Relationships and for Diagnostic/Therapeutic Targeting of Neurotoxic Amyloid Oligomers. <b>2020</b> , 21,		3
189	Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target. <b>2020</b> , 11, 590754		3
188	Peri-arterial pathways for clearance of $\beta$ -synuclein and tau from the brain: Implications for the pathogenesis of dementias and for immunotherapy. <b>2020</b> , 12, e12070		7
187	Vaccination against $\beta$ -Amyloid as a Strategy for the Prevention of Alzheimer's Disease. <b>2020</b> , 9,		4

186	Active immunotherapy and alternative therapeutic modalities for Alzheimer's disease. <b>2020</b> , 6, e12090		0
185	Nanomedicine-based immunotherapy for central nervous system disorders. <b>2020</b> , 41, 936-953		14
184	Amyloid- $\beta$ plaques may be reduced in advanced stages of cerebral amyloid angiopathy in the elderly. <i>Neuropathology</i> , <b>2020</b> , 40, 474-481	2	2
183	Harnessing regulatory T cell neuroprotective activities for treatment of neurodegenerative disorders. <b>2020</b> , 15, 32		19
182	Brain insulin resistance: role in neurodegenerative disease and potential for targeting. <b>2020</b> , 29, 333-348		44
181	Potential Role of Venular Amyloid in Alzheimer's Disease Pathogenesis. <b>2020</b> , 21,		14
180	Potential Therapeutic Approaches for Cerebral Amyloid Angiopathy and Alzheimer's Disease. <b>2020</b> , 21,		10
179	Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice. <b>2020</b> , 5, 28		9
178	Generation of Transgenic Cynomolgus Monkeys Overexpressing the Gene for Amyloid- $\beta$ Precursor Protein. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 75, 45-60	4-3	8
177	The role of the immune system in driving neuroinflammation. <b>2020</b> , 4, 2398212819901082		20
176	Yeast-Based A $\beta$ -15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer's Disease Transgenic Mice. <b>2020</b> , 8,		2
175	Invited Review - Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. <b>2020</b> , 46, 623-640		12
174	Engineered hepatitis B core virus-like particle carrier for precise and personalized Alzheimer's disease vaccine preparation via fixed-point coupling. <b>2020</b> , 19, 100575		3
173	Traitement de la maladie d'Alzheimer : une lueur au bout du tunnel ?. <b>2020</b> , 11, 46-48		
172	Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials. <b>2020</b> , 139, 104823		9
171	Amyloids in Site-Specific Autoimmune Reactions and Inflammatory Responses. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 2980	8.4	2
170	Learning from the Past: A Review of Clinical Trials Targeting Amyloid, Tau and Neuroinflammation in Alzheimer's Disease. <b>2020</b> , 17, 112-125		25
169	Development of a robust crystallization platform for immune receptor TREM2 using a crystallization chaperone strategy. <b>2021</b> , 179, 105796		3

168	A practical approach to the management of cerebral amyloid angiopathy. <b>2021</b> , 16, 356-369	7
167	Conversion from cilostazol to OPC-13015 linked to mitigation of cognitive impairment. <b>2021</b> , 7, e12182	0
166	Is $\beta$ -secretase a beneficial inactivating enzyme of the toxic APP C-terminal fragment C99?. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 296, 100489	5.4 15
165	The role of astrocytes in prion-like mechanisms of neurodegeneration.. <b>2022</b> ,	0
164	Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis. <b>2021</b> , 121, 2545-2647	128
163	Intranasal drug delivery for treatment of Alzheimer's disease. <b>2021</b> , 11, 411-425	6
162	Taxifolin: A Potential Therapeutic Agent for Cerebral Amyloid Angiopathy. <b>2021</b> , 12, 643357	2
161	Nutraceuticals and their Derived Nano-formulations for the Prevention and Treatment of Alzheimer's disease. <b>2021</b> ,	3
160	New App knock-in mice that accumulate wild-type human A $\beta$ s rapidly as AppNL-G-F mice exhibit intensive cored plaque pathology and neuroinflammation.	
159	Current Management and Therapeutic Strategies for Cerebral Amyloid Angiopathy. <b>2021</b> , 22,	3
158	Cerebral amyloid angiopathy and related inflammatory disorders. <b>2021</b> , 424, 117425	5
157	Amyloids: The History of Toxicity and Functionality. <b>2021</b> , 10,	3
156	Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses. <i>Journal of Alzheimer's Disease</i> , <b>2021</b> , 82, 71-105	4.3 7
155	Perivascular spaces and brain waste clearance systems: relevance for neurodegenerative and cerebrovascular pathology. <b>2021</b> , 63, 1581-1597	8
154	Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. <b>2021</b> ,	16
153	Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases. <b>2021</b> , 274, 119326	8
152	PEGylated superparamagnetic iron oxide nanoparticles (SPIONs) ameliorate learning and memory deficit in a rat model of Alzheimer's disease: Potential participation of STIMs. <b>2021</b> , 85, 145-159	3
151	Immunotherapeutics for AD: A Work in Progress. <b>2021</b> ,	0

150	The Development of Pharmacological Therapies for Alzheimer's Disease. <b>2021</b> , 10, 609-626		2
149	The Role of Adaptive and Innate Immunity in Alzheimer's Disease. <b>2021</b> , 213-232		
148	A third-generation mouse model of Alzheimer's disease shows early and increased cored plaque pathology composed of wild-type human amyloid $\beta$ peptide. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 297, 101004	5-4	5
147	Amyloid- $\beta$ and Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. <b>2021</b> , 15, 733857		8
146	Emotional Reactions to Music in Dementia Patients and Healthy Controls: Differential Responding Depends on the Mechanism. <b>2021</b> , 4, 205920432110101		2
145	Peptide Vaccines.		1
144	Understanding and Treating Alzheimer's Disease. <b>2006</b> , 49-70		1
143	Antidementiva. <b>2006</b> , 350-368		2
142	Cognitive Impairment in Transgenic A $\beta$ and Tau Models of Alzheimer's Disease. <b>2007</b> , 77-91		1
141	Amyloid Imaging with PET in Alzheimer's Disease, Mild Cognitive Impairment, and Clinically Unimpaired Subjects. <b>2009</b> , 119-147		4
140	Immunotherapy for Alzheimer's disease: DNA- and protein-based epitope vaccines. <b>2014</b> , 1143, 259-81		10
139	The Involvement of A $\beta$ in the Neuroinflammatory Response. <b>2007</b> , 52-82		1
138	Rationale and prospects for drugs that target nicotinic acetylcholine receptors. <b>2004</b> , 49-68		1
137	Tyrosine Kinase Inhibitors and Neurodegenerative Disorders. <b>2016</b> , 81-91		1
136	Antidementiva. <b>2007</b> , 351-368		1
135	Antidementiva. <b>2008</b> , 313-326		2
134	Antidementiva. <b>2004</b> , 281-299		1
133	The Dementias. <b>2008</b> , 1855-1907		1

132	Noninfectious disease vaccines. <b>2008</b> , 1275-1281	1
131	Alzheimer's Disease. <b>2010</b> , 411-420	1
130	Dementias. <b>2012</b> , 1534-1582	4
129	Amyloid Imaging and (What is "Normal") Aging. <b>2009</b> , 191-244	1
128	40 Hz acoustic stimulation decreases amyloid beta and modulates brain rhythms in a mouse model of Alzheimer's disease.	1
127	Detangling Alzheimer's disease. New insights into the biological bases of the most common cause of dementia are pointing to better diagnostics and possible therapeutics. <b>2003</b> , 2003, oa2	6
126	Immunotherapy for Alzheimer's disease. <b>2004</b> , 2004, pe29	5
125	Immune shaping and the development of Alzheimer's disease vaccines. <b>2005</b> , 2005, pe35	3
124	Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. <b>2003</b> , 112, 415-22	122
123	Amyloid beta and Alzheimer disease therapeutics: the devil may be in the details. <b>2003</b> , 112, 321-3	18
122	Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. <b>2004</b> , 114, 1624-34	330
121	Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease. <b>2005</b> , 115, 2423-33	121
120	Anti-Aβ42- and anti-Aβ40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. <b>2006</b> , 116, 193-201	155
119	Alzheimer Disease. <b>2016</b> , 22, 419-34	62
118	Identification of beta-secretase (BACE1) substrates using quantitative proteomics. <b>2009</b> , 4, e8477	140
117	Prophylaxis and treatment of Alzheimer's disease by delivery of an adeno-associated virus encoding a monoclonal antibody targeting the amyloid Beta protein. <b>2013</b> , 8, e57606	21
116	Enhanced Aβ(1-40) production in endothelial cells stimulated with fibrillar Aβ(1-42). <b>2013</b> , 8, e58194	12
115	Decrease in blood pressure and regression of cardiovascular complications by angiotensin II vaccine in mice. <b>2013</b> , 8, e60493	36

114	Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. <b>2013</b> , 8, e72301	159
113	Investigating interventions in Alzheimer's disease with computer simulation models. <b>2013</b> , 8, e73631	23
112	Development of a new DNA vaccine for Alzheimer disease targeting a wide range of a $\beta$ species and amyloidogenic peptides. <b>2013</b> , 8, e75203	21
111	Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles. <b>2017</b> , 12, e0181844	15
110	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. <b>2020</b> , 42, 431-441	18
109	How to get from here to there: macrophage recruitment in Alzheimer's disease. <b>2011</b> , 8, 156-63	48
108	The Amyloid Cascade Hypothesis in Alzheimer's Disease: It's Time to Change Our Mind. <b>2017</b> , 15, 926-935	151
107	Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. <b>2010</b> , 9, 207-16	28
106	Drug targets from genetics: $\beta$ -synuclein. <b>2011</b> , 10, 712-23	8
105	Mechanism-based treatments for Alzheimer's disease. <b>2009</b> , 11, 159-69	13
104	A Review on Current Strategies and Future Perspective in Respect to Alzheimer's Disease Treatment. <b>2015</b> , 6, 1-15	4
103	Early active immunization with A $\beta$ KLH vaccine reduces tau phosphorylation in the hippocampus and protects cognition of mice. <b>2020</b> , 15, 519-527	4
102	Fibrillar A $\beta$ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. <b>2020</b> , 9,	36
101	Autoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implications. <i>Journal of Biomedical Research</i> , <b>2016</b> , 30, 361-372	1.5 46
100	Past, present and future of therapeutic strategies against amyloid- $\beta$ peptides in Alzheimer's disease: a systematic review. <b>2021</b> , 72, 101496	13
99	Phospholipase C $\alpha$ regulates endocannabinoid and eicosanoid networks in innate immune cells. <b>2021</b> , 118,	1
98	Processo Inflamatório e Neuroimunomodulação na Doença de Alzheimer. <b>2011</b> , 19, 300-313	
97	[Development of therapies of Alzheimer's disease]. <b>2003</b> , 40, 473-5	

96 Alzheimer's vaccine setback confirmed.

95 Antidementiva. **2004**, 194-209

94 Perspectives of Immunotherapy against TSE. **2004**, 385-387

93 Demenzen. **2005**, 661-684

92 Amyloid Therapeutic Strategies for Alzheimer's Disease.

0

91 Alzheimer's Disease. **2005**, 632-650

90 Immunotherapeutic Approaches for Alzheimer's Disease. **2006**, 197-211

89 Entzündung und Alzheimer Krankheit. **2007**, 20, 39-45

88 Neuroinflammation and Mitochondrial Dysfunction in Alzheimer's and Prion's Diseases. **2007**, 309-331

87 The Rationale for an Immunological Approach to Alzheimer's Therapeutics. **2007**, 141-148

86 Antidementiva. **2008**, 305-317

1

85 ANTI-AMYLOID-IMMUNOTHERAPY AS A TREATMENT FOR ALZHEIMER'S DISEASE. **2008**, 295-318

1

84 An Overview of Protein Misfolding Diseases.

83 La maladie d'Alzheimer : des lésions fibreuses aux perspectives thérapeutiques. **2008**, 192, 363-380

2

82 Tau Transgenic Mouse Models in Therapeutic Development. **2009**, 41-48

81 Antidementiva. **2009**, 309-320

80 Antidementiva. **2010**, 331-342

79 Synapses and Alzheimer's Disease: Effect of Immunotherapy?. **2011**, 269-287



78 Pathological Validation of Animal Models of Dementia. **2011**, 99-141

77 Antidementia. **2011**, 339-350

76 Future treatments of memory loss. **2011**, 199-213

75 The Functions of the Amyloid Precursor Protein Gene and Its Derivative Peptides: III Pharmacological Studies. **2011**, 02, 397-409

74 Thinking Outside the Box in Alzheimer Disease Treatment.

73 Antidementia. **2012**, 339-350

72 Nasal mucosal inhalation of amyloid-beta peptide 3-10 defective adenovirus attenuates cytotoxicity induced by beta-amyloid (1-42). **2014**, 9, 872-7

1

71 Roles in Immune Responses. **2014**, 115-144

70 Merits and Demerits of Vaccination for Patients with Neurological Diseases. **2014**, 60, s53-s59

69 Measurement and Analysis of Cognitive Brain Functions for Early Detection of Alzheimer's Disease. **2014**, 21, 1-7

68 Expression of A $\beta$ C Fusion Protein in Transgenic Potato. **2014**, 32, 375-381

67 A Rapidly Progressive Dementia. **2015**, 1-7

66 Conformational Disease and RNA Disease Theory in the Context of Neurodegenerative Diseases. **2015**, 3-22

65 Immunotherapeutic Approaches Against Amyloid- $\beta$  In Drug Discovery for Alzheimer's Disease. **2015**, 395-415

64 Neuropsychological Screening and Advanced Neuropsychological Tests. **2016**, 51-90

63 FDG PET: Imaging Cerebral Glucose Metabolism with Positron Emission Tomography. **2016**, 247-270

1

62 SARS Vaccines. **2016**, 942-954

61 Drug Management of the Dementias. **2017**, 1-5

60	A Vaccine Kit for Prevention and Therapy of Alzheimer's Disease in a Transgenic Mouse Model. <b>2018</b> , 3, 12-18		
59	Therapeutic Vaccines Targeting Alzheimer's Disease. <b>2019</b> , 9-20		1
58	Is Alzheimer disease a failure of mobilizing immune defense? Lessons from cognitively fit oldest-old. <b>2019</b> , 21, 7-19		1
57	Fibrillar A $\beta$ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.		1
56	Demenzkerkrankungen. <b>2020</b> , 295-321		
55	Immunotherapy in Neurodegenerative Disorders. <b>2021</b> , 117-136		
54	Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric $\beta$ -synuclein accumulation in the brain and gut. <i>Acta Neuropathologica</i> , <b>2021</b> , 1	14.3	1
53	Neuropathology of Alzheimer's Disease. <i>Neurotherapeutics</i> , <b>2021</b> ,	6.4	11
52	Endothelial expression of human APP leads to cerebral amyloid angiopathy in mice.		1
51	Oral A $\beta$ Vaccine Using a Recombinant Adeno-Associated Virus Vector in an Alzheimer's Disease Mouse Model. <b>2008</b> , 265-272		
50	Intraneuronal A $\beta$ and Alzheimer's Disease. <b>2008</b> , 297-304		
49	Physiologic and Neurotoxic Properties of A $\beta$ Peptides. <b>2007</b> , 179-197		
48	Antidementiva. <b>2008</b> , 643-665		
47	Jugend ist Stärke und Alter ist Schwäche der Reparaturmechanismen. <b>2008</b> , 57-65		
46	Biomarkers of Alzheimer disease in plasma. <i>Neurotherapeutics</i> , <b>2004</b> , 1, 226-234	6.4	
45	Pathogenesis of Alzheimer's disease. <i>Clinical Interventions in Aging</i> , <b>2007</b> , 2, 347-59	4	148
44	New treatment strategies for Alzheimer's disease: is there a hope?. <i>Indian Journal of Medical Research</i> , <b>2013</b> , 138, 449-60	2.9	20
43	Novel immunological approaches for the treatment of Alzheimer's disease. <b>2014</b> , 14, 139-151		

42	Amyloid-beta Alzheimer targets - protein processing, lipid rafts, and amyloid-beta pores. <i>Yale Journal of Biology and Medicine</i> , <b>2016</b> , 89, 5-21	2.4	57
41	CD4+ effector T cells accelerate Alzheimer's disease in mice. <i>Journal of Neuroinflammation</i> , <b>2021</b> , 18, 272	10.1	3
40	Microglia and immunotherapy in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , <b>2021</b> ,	3.8	5
39	Vessels Sing Their ARIAs: The Role of Vascular Amyloid in the Age of Aducanumab.. <i>Stroke</i> , <b>2022</b> , 53, 298-302	6.7	0
38	An autopsy case of amyloid angiopathy-related cerebellar hemorrhage.. <i>Neuropathology</i> , <b>2022</b> ,	2	0
37	Histopathological correlates of haemorrhagic lesions on magnetic resonance imaging in immunized Alzheimer's disease cases.. <i>Brain Communications</i> , <b>2022</b> , 4, fcac021	4.5	0
36	New Perspectives for Treatment in Alzheimer's Disease. <b>2022</b> , 199-225		
35	Europium-Doped Cerium Oxide Nanoparticles for Microglial Amyloid Beta Clearance and Homeostasis.. <i>ACS Chemical Neuroscience</i> , <b>2022</b> ,	5.7	0
34	ATRI and ACTC: Academic Programs to Accelerate Alzheimer's Disease Drug Development. <b>2022</b> , 177-189		
33	Role of Animal Models in Alzheimer's Disease Drug Development. <b>2022</b> , 73-94		
32	Endothelial expression of human amyloid precursor protein leads to amyloid $\beta$ in the blood and induces cerebral amyloid angiopathy in knock-in mice.. <i>Journal of Biological Chemistry</i> , <b>2022</b> , 101880	5.4	0
31	T Cell-Mediated Autoimmunity in Glaucoma Neurodegeneration.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 803485	4.8	0
30	Data_Sheet_1.doc. <b>2019</b> ,		
29	Disease-Modifying Therapies for Alzheimer's Disease: More Questions than Answers.. <i>Neurotherapeutics</i> , <b>2022</b> , 1	6.4	2
28	Amyloid- $\beta$ in Brain Aging and Alzheimer's Disease. <b>2022</b> , 335-354		
27	Alzheimer disease neuropathology in a patient previously treated with aducanumab.. <i>Acta Neuropathologica</i> , <b>2022</b> ,	14.3	1
26	[Therapy Developments in Alzheimer's Disease].. <i>Fortschritte Der Neurologie Psychiatrie</i> , <b>2022</b> ,	0.5	
25	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2022</b> , 81, 387-413	3.1	0

24	Mouse Models of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 15,	6.1	1
23	AAV-mediated neuronal expression of a scFv antibody selective for A $\beta$ oligomers protects synapses and rescues memory in Alzheimer models.		
22	A comparison of cerebral amyloid angiopathy in the cerebellum and CAA -positive occipital lobe of 60 brains from routine autopsies. <i>Neuropathology</i> ,	2	
21	Acquired immunity and Alzheimer's disease. <i>Journal of Biomedical Research</i> , <b>2022</b> , 36, 1	1.5	
20	Joint Computational/Cell-Based Oligomerization for Screening Inhibitors of Tau Assembly: A Proof-of-Concept Study. <i>Journal of Alzheimer's Disease</i> , <b>2022</b> , 1-13	4.3	o
19	Amyloid- $\beta$ -targeting immunisation in aged non-human primate ( <i>Microcebus murinus</i> ).		
18	Virus-like particle vaccinology, from bench to bedside.		4
17	Basics of amyloid $\beta$ -protein in Alzheimer's disease. <b>2022</b> , 73-89		o
16	The RSNA QIBA Profile for Amyloid PET as an Imaging Biomarker for Cerebral Amyloid Quantification. <i>jnumed</i> .122.264031		o
15	Blood-brain barrier leakage and perivascular inflammation in cerebral amyloid angiopathy.		o
14	Immunosenescence of brain accelerates Alzheimer's disease progression. <b>2023</b> , 34, 85-101		o
13	Vascular Considerations for Amyloid Immunotherapy. <b>2022</b> , 22, 709-719		o
12	AAV-mediated neuronal expression of a scFv antibody selective for A $\beta$ oligomers protects synapses and rescues memory in Alzheimer models. <b>2022</b> ,		o
11	Capillary angiopathy and aquaporin-4 after A $\beta$ immunisation in Alzheimer's disease -potential relevance to Amyloid-Related Imaging Abnormalities.		o
10	Investigation of the Structure of Full-Length Tau Proteins with Coarse-Grained and All-Atom Molecular Dynamics Simulations.		o
9	Development of monoclonal antibody therapeutics for alzheimer's disease. <b>2022</b> , 36, 148		o
8	Experimental approaches for altering the expression of Abeta-degrading enzymes.		1
7	Microglial autophagy in Alzheimer's disease and Parkinson's disease. 14,		1

- 6 Amyloid- $\beta$ -targeting immunisation in aged non-human primate (*Microcebus murinus*). **2023**, 109, 63-77 o
- 5 Animal Models of Amyloid/PS-1 Pathology. **2011**, 15-38 o
- 4 Advances in Alzheimer's disease's pharmacological treatment. 14, 1
- 3 Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. **2023**, 28, 1283 o
- 2 Lecanemab (BAN2401): an anti- $\beta$ -amyloid monoclonal antibody for the treatment of Alzheimer disease. **2023**, 32, 89-94 o
- 1 Vaccines for prion diseases: a realistic goal?. **2023**, 392, 367-392 o